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ABSTRACT OF DISSERTATION

LOW DENSITY LIPOPROTEIN RECEPTOR AND ALZHEIMERS DISEASE
Since apoE allele status is the predominant Alzheimers disease (AD) genetic risk factor,
functional single nucleotide polymorphisms (SNPs) in brain apoE receptors represent
excellent candidates for association with AD. Therefore, three low density lipoprotein
receptor (LDLR) SNPs were evaluated by TaqMan allelic discrimination assays for
association with AD and I found that certain haplotypes alter the odds of AD. A SNP
within LDLR exon 12, rs688, was identified in silico as neutralizing a putative exon
splicing enhancer (ESE). Since LDLR is a major apoE receptor in the brain, I
hypothesized that rs688 modulates LDLR splicing in neural tissues and associates with
AD. To evaluate this hypothesis, I analyzed splicing patterns in human hippocampus
samples and established that this SNP was associated with significantly decreased LDLR
exon 12 splicing efficiency when the minor allele T is present in vivo. Lastly, I evaluated
whether rs688 associates with AD by genotyping DNA from the Religious Orders Study
(ROS) series. The rs688T/T genotype was associated with increased AD odds in males,
but not in females, in a dataset consisting of 1,457 men and 2,055 women drawn from
three case-control series. The rs688T/T genotype was associated with increased AD odds
in males (recessive model, odds ratio (OR) of 1.49, 95% confidence interval (CI) of 1.131.97, uncorrected p=0.005), but not in females. In summary, these studies identify a
functional apoE receptor SNP that is associated with AD in a sex-dependent fashion.
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Chapter One: Introduction and Background

Alzheimers Disease
Impact
Alzheimers Disease (AD) is a devastating disorder. It is not considered a normal
part of aging even though increasing age is an inescapable and pervasive risk factor
(Giannakopoulos, Bouras et al. 2008). One in 10 individuals over 65 and nearly half of
those over 85 are affected (Evans, Funkenstein et al. 1989). The number of Americans
with AD has more than doubled since 1980 to an estimated 4.5 million and will continue
to grow as the proportion of elderly in the population increases. It could be as high as 16
million by 2050 (Hebert, Scherr et al. 2003). The impact on individuals, families and the
health care system makes the disease one of the nation’s greatest medical, social and
fiscal challenges especially in view of the burgeoning proportion of the elderly. Average
survival time is affected by age at diagnosis and severity of other medical conditions
(Larson, Shadlen et al. 2004). According to estimates used by the Alzheimer’s
Association and the National Institute on Aging national direct and indirect annual costs
of caring for individuals with AD are at least $100 billion (Ernst and Hay 1994). The
implications of interventions or therapies that could delay onset of the disease could have
profound effects prevalence. So much so a five year delay could decrease the number of
individuals with AD by nearly fifty percent after fifty years (Brookmeyer, Gray et al.
1998). The critical breakthroughs have been achieved to a large extent through advances
in the understanding of the biochemical pathology and genetics as explained below.
Pathology
The description rendered by the German neuropsychiatrist Alois Alzheimer in 1906 is
relevant even after almost a century. Grossly, there is atrophy of the brain and dilatation
of the ventricles. Microscopically, the numbers of neuritic plaques and neurofibrillary
tangles are vastly in excess of those seen in older persons without dementia. They are
abundantly present in the amygdala, hippocampus and neocortex in AD. Indeed, the
current pathologic criteria for AD are based on the demonstration of sufficient numbers
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of these hallmark lesions during autopsy. Experienced physicians, following NINCDSADRDA (National Institute of Neurological and Communicative Diseases and
Stroke/Alzheimer's Disease and Related Disorders Association) criteria, can diagnose
possible or probable AD with up to 90% accuracy in live patients (McKhann, Drachman
et al. 1984).
Plaques are extracellular deposits of proteinaceous amyloid core surrounded by
dystrophic neurites. The amyloid beta (A ) is a result of proteolytic cleavage of the larger
APP. But whether the deposition of amyloid initiates or triggers AD or is just a relic
marking neuronal degeneration is still debated (Mattson, Carney et al. 1995). Also A
oligomers may be equally toxic and deleterious (Haass and Selkoe 2007; Walsh and
Selkoe 2007). Clinical trials of experimental drugs targeting amyloid that are under way
should help clarify the role of plaques and may lend further credence to the ‘amyloid
hypothesis’.
Neuro fibrillary tangles (NFTs) are intracellular accumulations of the cytoskeletal protein
tau that is abnormally phosphorylated and arranged in the form of paired helical filaments
(Arnaud, Robakis et al. 2006). The limbic and association cortices of AD brains
demonstrate innumerable NFTs. Subcortical nuclei that project to these regions are also
affected. These nuclei include the cholinergic basal forebrain complex, the locus ceruleus
and the median raphe nuclei (Arnold, Hyman et al. 1991; Arriagada, Growdon et al.
1992). Though this protein does not find a prominent role in the ‘amyloid hypothesis’, it
is still an active area of intense investigation (Haroutunian, Davies et al. 2007).
Although the decline in cholinergic system markers such as choline acetyltransferase and
acetylcholinesterase has been correlated with both the degree of dementia and the number
of neuritic plaques, cholinergic loss should not be considered the preeminent
neurotransmitter alteration in AD because the neuronal loss is not restricted to cholinergic
neurons.
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Risk factors
AD is a progressive neurological disorder with complex etiology that encompasses both
environmental and genetic risk factors.
The existence of environmental risk factors is suggested by twin studies. Though
monozygotic twins have a high degree of concordance for AD, it is still less than 40%.
Further, even when both identical twins develop the disease, the presentation and clinical
course is not identical (Breitner and Murphy 1992; Small, Leuchter et al. 1993; Raiha,
Kaprio et al. 1996). Anti-inflammatory drug use constitutes one “environmental” factor
that lowers AD risk, as individuals receiving high doses, e.g., arthritic individuals, are at
a lower AD risk (reviewed in (McGeer, Schulzer et al. 1996)). A history of head trauma
and certain polymorphisms in the inflammatory mediator interleukin-2 (see below) have
been associated with AD, providing further support for inflammation playing a role in
AD (Guo, Cupples et al. 2000; Mrak and Griffin 2000). A role for estrogen as a
neuroprotectant has also been suggested (reviewed in (Behl 2002)). Life style choices
such as controlling blood pressure, weight and cholesterol levels; exercising both body
and mind; and staying socially active may not only promote successful healthy aging but
it may also help reduce the risk of developing AD.
As seen in other chronic diseases of the elderly, first-degree relatives seem to have a
greater risk of disease. Several robust genetic risk factors have been identified for AD
over the past several years. Three genes have been implicated in familial AD (FAD),
including APP, presenilin-1 and presenilin-2; mutations in these genes produce AD
marked by autosomal dominance, early disease onset (can strike individuals as early as
their 30s and 40s (Bird, Sumi et al. 1989)), high penetrance, and relative rarity, on the
order of a few hundred families worldwide (reviewed in (Pericak-Vance, Grubber et al.
2000; Selkoe 2001)). APP is located in chromosome 21 and it was known widely that
nearly all Down’s syndrome (Trisomy 21) patients developed AD. Because each of the
mutated forms of these genes enhance the production of Aß or of Aß that is longer, and
hence more likely to form toxic oligomeric aggregates, the discovery of these genes has
suggested that genes that impact on Aß production or clearance could be critical to the
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disease (Goate, Chartier-Harlin et al. 1991; Citron, Oltersdorf et al. 1992; Cai, Golde et
al. 1993; Roher, Lowenson et al. 1993; Suzuki, Cheung et al. 1994; 1995; Levy-Lahad,
Wijsman et al. 1995; Duff, Eckman et al. 1996).
This is the basic tenet for the ‘amyloid hypothesis’ which assigns a central causative role
to abnormal amyloid processing. Amyloid precursor protein (APP) undergoes proteolytic
cleavage by several different secretases. The bulk of the APP circumvents generation of
A when processed by -secretase releasing the neurotrophic ectodomain of APP into the
CSF (Sisodia 1992; Haass and Selkoe 1993). On the other hand - and -secretases
working in tandem can generate the A peptide (Sisodia 1992; Haass and Selkoe 1993).
Due to slippage in the site of cleavage by -secretase the C terminal of amyloid is
variable resulting in different species upto 43 amino acids long. The major species is 40
amino acids long, but of special interest is 42 which is ~10% of the amyloid peptides but
aggregates with alacrity and could be a nidus for plaque formation and help recruit more
amyloid (Iwatsubo, Odaka et al. 1994).
Several genes have been hypothesized to contribute to the much more common
“sporadic”, late onset, AD (LOAD) which affects individuals over age 65. The premier
example of a genetic risk factor for LOAD is apoE4, which surfaced on a biochemical
screen of CSF proteins that can bind A (Strittmatter, Saunders et al. 1993). This is
remarkable in that (i) multiple groups have confirmed that even a single copy of apoE4
increases susceptibility to AD, (ii) apoE4 has been associated with earlier disease onset,
and (iii) apoE4 is associated with increased brain A in affected individuals ((Roses
1994); reviewed in (Pericak-Vance, Grubber et al. 2000)). These effects of apoE on Aß
burden can be seen in mice as well, with studies in mice deficient for apoE or transgenic
for human apoE supporting a role for apoE in Aß fibrillogenesis and neuritic plaque
formation (Holtzman, Bales et al. 1999; Holtzman, Bales et al. 2000; Holtzman, Fagan et
al. 2000). In summary, apoE4 (i) provides a point of reference for evaluating additional
LOAD risk factors and (ii) must be considered when evaluating additional genetic
polymorphisms to ensure that an underlying apoE4 does not dictate an apparent
association between these additional SNPs and AD.
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Overall, apoE4 and the rare FAD mutations appear to account for approximately 50% of
the genetic risk of AD (Pericak-Vance, Grubber et al. 2000). One recent simulation
analysis suggests the existence of at least four additional genes with an impact similar to
ApoE4 on age of AD onset (Warwick Daw, Payami et al. 2000).
Cholesterol
Physiology
Cholesterol is a vital component of all mammalian cell membranes. It confers important
properties such as membrane fluidity and permeability. Apart from its structural function
cholesterol is also the precursor of cellular signaling molecules such as oxysterol in the
brain (Simons and Ikonen 2000), steroid hormones in endocrine tissue, Vitamin D in skin
cells (Ohvo-Rekila, Ramstedt et al. 2002). It is also necessary for bile acid synthesis in
the liver. Cholesterol biosynthesis is known to occur in the endoplasmic reticulum, and
also in the peroxisomes (Reinhart, Billheimer et al. 1987) of most eukaryotic cells.
At the cellular level there is a fine balance between biosynthesis and uptake of lipoprotein
cholesterol into cells and esterification. The process by which peripheral cholesterol is
returned to the liver for catabolism and excretion is known as reverse cholesterol
transport (RCT) (Fielding and Fielding 1995). This is important in order to achieve sterol
homeostasis because extrahepatic tissue cannot catabolize cholesterol.
CNS Cholesterol
The brain and spinal cord harbors 25 percent of all unesterified cholesterol in an
individual while accounting for only 2% of the body mass. Apart from the plasma
membrane cholesterol is also a critical component of myelin and is deposited early in
development (Spady and Dietschy 1983). The daily turnover rate of cholesterol in human
brain is believed to be only 0.02% while it is a 100 times more rapid in the whole body
(Wilson 1970). It is estimated that cholesterol has a half life of nearly six months in the
brain (Andersson, Elmberger et al. 1990).
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Blood Brain Barrier
The blood–brain barrier (BBB) is impermeable to the plasma lipoproteins and
secludes the central nervous system (CNS) from the peripheral cholesterol pool (Danik,
Champagne et al. 1999). Local tissue demand for cholesterol is supplied by synthesis
within the brain (Morell and Jurevics 1996). Even though the BBB is a formidable barrier
that preserves the cellular milieu in the brain, the component cerebral microvasculature
could be damaged in the presence of disease such as stroke (Hulthe, Wikstrand et al.
1997) and possibly AD (Skoog, Wallin et al. 1998). And this is process occurs early in
the process well before the manifestation of the disease.
Only a miniscule amount of cholesterol is transported from the brain to the CSF via an
ApoE-dependent mechanism. The majority of brain cholesterol is converted to 24hydroxycholesterol by the enzyme 24-hydroxylase which is expressed predominantly in
the brain. This metabolite readily crosses the BBB, and helps sustain brain cholesterol
homeostasis. This oxysterol could potentially serve as a biomarker for cholesterol
turnover in the brain (Lund, Guileyardo et al. 1999).
Animal models of hypercholesterolemia and AD pathology
A high cholesterol diet in animal models has been shown to increase A formation
and deposition. Cholesterol-fed rabbits are prone to accumulate A in the brain and this
deposition can be reversed by withholding the dietary cholesterol (Sparks, Scheff et al.
1994; Sparks 1996). A double transgenic mouse model over expressing mutant APP and
presenilin-1 manifest elevated numbers and size of A deposits in the brains in response
to cholesterol (Refolo, Malester et al. 2000). Cholesterol-lowering drug treatment of these
mice decreased not only plasma cholesterol, but also brain A generation and deposition
(Refolo, Pappolla et al. 2001). The reversible nature of the pathology gives hope to the
notion that AD is treatable if appropriate therapeutic modalities are availed of at an early
stage in the disease process.
Cholesterol could influence the pathological processes in AD as evidenced by: (1) the
higher risk of AD when midlife plasma cholesterol is elevated; (2) a decrease in the
prevalence of AD by cholesterol-lowering drugs; and (3) the role of intracellular
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cholesterol in regulating the processing of APP and hence generation of A peptides that
accumulate as amyloid plaques in the brains and in cerebral vasculature of AD patients.
Thus genes involved in cholesterol metabolism could influence AD.
ApolipoproteinE
ApolipoproteinE (ApoE), a 34 kDa secreted protein product of the gene located in
chromosome 19q13.3, is abundantly produced in the brain, and is also an essential
constituent of various lipoproteins(Wilson, Mau et al. 1994). Transplantation studies
indicate that CNS apoE is synthesized locally (Linton, Gish et al. 1991) by astrocytes and
microglia (Pitas, Boyles et al. 1987; Ladu, Reardon et al. 2000). Freshly synthesized glial
derived apoE bearing particles are discoidal but starts maturing in shape and lipid content
so much so when it reaches the CSF the particles are 15 20 nm spheres bearing
additional apoA1 and resemble HDL particles (LaDu, Gilligan et al. 1998; Demeester,
Castro et al. 2000; Koch, Donarski et al. 2001).
ApoE variants
There are three alleles of which ApoE3 is the most prevalent and has following
amino acids at the indicated positions (Cys112, Arg158). The other two variants differ
only by a single amino acid substitution: APOE2 (Cys112, Cys158), and APOE4
(Arg112, Arg158) (Mahley 1988). ApoE4 was identified to be a genetic risk factor of AD
in 1993 (Corder, Saunders et al. 1993), a finding that has now been well replicated in a
multitude of studies. So much so, the genetic association of apoE4 with AD can be tested
as an internal positive control in association studies of novel candidate genes (Finckh
2003).
In the early days following this discovery, it was a puzzle as to how apoE was
mechanistically linked to AD and even now after more than a decade of research the
picture is far from complete. Cholesterol redistribution brought about by apoE is thought
to facilitate the repair and maintenance of neuronal membranes and myelin, and this is
especially helpful in the stressful setting of CNS injury or disease which can further
induce synthesis of apoE (Ignatius, Gebicke-Harter et al. 1986; Ignatius, Gebicke-Haerter
et al. 1987). Thus allele specific outcomes of disease status could be attributed at least
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partly to this mechanism. For instance apoE4 is associated with poor outcomes in
different types of neuronal damage including head trauma, cerebral hemorrhage, and
stroke (MO, Muir et al. 1998; Buttini, Orth et al. 1999; Liaquat, Dunn et al. 2002).
More specifically in the setting of AD apoE could directly interact with APP (Hass,
Weidemann et al. 2001), or A [reviewed and discussed in (Tomiyama, Corder et al.
1999)] or indirectly influence these proteins by binding to its receptors and competing
them away and/or altering signaling.
Allele specific effects
In the periphery apoE genotype can be correlated with plasma LDL cholesterol
(LDL-C), where apoE4 is associated with the highest LDL-C levels, apoE2 with lowest
levels, and apoE3 with intermediate measurements (Menzel, Kladetzky et al. 1983).
ApoE4 is also a significant risk factor for coronary artery disease, which is probably on
account of differential clearance of VLDL and chylomicron (Knouff, Hinsdale et al.
1999; Welty, Lichtenstein et al. 2000; Lahoz, Schaefer et al. 2001). Therapeutic response
to statin therapy can be correlated with apoE genotype as well. Efficacy in LDL reduction
with pravastain treatment is greatest in apoE2, smallest in apoE4, and intermediate with
apoE3 reflecting binding affinities of these particles with their receptors (Ordovas,
Lopez-Miranda et al. 1995).
The age of onset for AD has been associated with apoE variants, such that apoE4
homozygotes have a mean age of onset of <70 years which is about 8 years earlier than
apoE3 homozygotes (Corder, Saunders et al. 1993; Strittmatter and Roses 1995). This
differential effect of the isoforms on the pathologic course of AD is mirrored by the
differential binding affinity of the various isoforms with their receptors (apoE4 > apoE3
> apoE2). For e.g. apoE2 which binds very poorly to the receptors, may be protective in
AD (Saunders 2000).
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Low density lipoprotein receptor:
Gene Structure
The low density lipoprotein receptor (LDLR) gene (GeneID: 3949) consists of 18
exons, which correspond closely to the structural units of the protein. LDLR is a striking
example of a mosaic protein encoded by a gene that was assembled by exon shuffling.
LDLR transcription is regulated efficiently by sterols. The constitutive transcription
factor, Sp1 can bind to two repeat elements in the promoter region. The sterol-responsive
element-1 (SRE-1) is the third site on the promoter, and this is recognized by SRE-1
binding proteins (SREBPs) which can then ramp up the transcription rate. The LDLR is
expressed in all tissues of the body at variable levels, including the brain. Mutations in
this gene cause the autosomal dominant disorder, familial hypercholesterolemia (FH).
The disorder leads to markedly elevated plasma levels of LDL-cholesterol, the deposition
of cholesterol on blood-vessel walls, premature atherosclerosis and coronary artery
disease (CAD).
Homologues
This gene family arose with the evolution of multicellular lifeforms underscoring
its importance in moving cargo and communication between cells, and is remarkably
conserved with time. Absence of functional LRP1 in C. elegans results in improper
molting and failure to thrive (Yochem, Tuck et al. 1999). Six Drosophila melanogaster
genes belong to the LDLR family. Mutants identified include (1.) yolkless, which leads to
arrested embryonic development due to inability to accumulate yolk in the egg
(Schonbaum, Lee et al. 1995) and (2.) arrow, the orthologue of mammalian LRP5 and
LRP6, which is required for Wg/Wnt signaling (Wehrli, Dougan et al. 2000).
The mammalian LDLR gene family consists of seven core members, including LDLR,
the LDLR-related protein (LRP, a.k.a. LRP1), LRP1b, megalin (a.k.a. gp330 or LRP2),
the VLDL receptor (VLDLR), Apolipoprotein E receptor-2 (ApoER2, a.k.a. LRP8), and
a multiple epidermal growth factor (EGF) repeat containing protein, MEGF7 (reviewed
in (Herz and Bock 2002)).
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Distinguishing features of ‘core members’
By popular consensus ‘core members’ are expected to display all of the following
five distinct domains or sequence motifs: (a) cysteine-rich ligand binding domain, (b)
epidermal growth factor type cysteine-rich repeats, (c) YWTD domains that form a fold
of -pleated sheets resembling a propeller structure (Springer 1998; Jeon, Meng et al.
2001), (d) a single membrane spanning segment, and (e) a cytoplasmic tail containing
one or more 'NPxY' (Asp-Pro-any amino acid-Tyr) tetraamino acid motifs (Krieger and
Herz 1994; Willnow 1999; Herz, Gotthardt et al. 2000). The only other feature that is
allowable is the optional O-linked sugar domain.
Some three other proteins LRP5, LRP6, and LR11 (a.k.a. SORLA) are still considered
close relatives of the core family members despite not meeting all the structural
requirements. All LDLR family members share an ability to bind the receptor-associated
protein (RAP), which acts as a molecular chaperone in the endoplasmic reticulum (ER)
where it facilitates proper folding (Bu, Geuze et al. 1995; Bu, Rennke et al. 1997;
Obermoeller-McCormick, Li et al. 2001) as well as preventing the precocious interaction
with ligands that might be traveling in the same compartment along with the receptors
(Willnow, Armstrong et al. 1995; Willnow, Rohlmann et al. 1996).
Receptor mediated endocytosis
LDLR belongs to a gene family of cell surface proteins involved in receptormediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally
bound at the cell membrane by the transmembrane LDLR and internalized into the cell.
The LDL dissociates from its receptors in the acidic environment of the endosome. The
LDLR protein is then returned to the plasma membrane. Regardless of ligand binding
status, LDLR typically makes one round trip into the cell and back to the plasma
membrane every 10 minutes, making a total of several hundred trips in its 20-hour lifespan.
By contrast the cargo i.e. LDL particle is broken down upon fusion with lysosomes. The
apo-B protein is degraded to amino acids and the cholesterol esters are hydrolyzed to
fatty acids and cholesterol. The free cholesterol is made available for repression of
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microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the
rate-limiting step in cholesterol synthesis. Simultaneously, a reciprocal stimulation of
cholesterol ester synthesis favors storage and utilization of excess cholesterol. Thus
abundant imported cholesterol inhibits synthesis by the cell of both cholesterol and LDL
receptor protein.
Critical domains involved in ligand binding and release
LDLR can bind to the apolipoprotein B-100 bearing LDL as well as the
apolipoprotein E studded beta-VLDL. Lipid association can change the conformation of
apoE and improve the affinity of apoE for its receptor. Out of the seven LDLR class A
repeats, numbers 4 and 5 is sufficient to bind apoE-containing ligands, as revealed by
LDLR-derived "minireceptor" studies (Fisher, Abdul-Aziz et al. 2004).
The propeller could well emerge as an intramolecular mechanism for displacing
lipoprotein particles. The extracellular domain of LDLR maintains an extended linear
shape at neutral pH when it is amenable to ligand binding, but assumes a more compact
shape at acidic pH as found in endosomes. The R1–R4 fragment normally does not
associate with the rest of the extracellular domain at neutral pH, but it has been shown to
do so at an acidic pH and this could be a mechanism whereby the ligand is displaced
competitively (Rudenko, Henry et al. 2002).
LDLR variants result in Familial hypercholesterolemia
The ground breaking work by Brown and Goldstein (Brown and Goldstein 1986)
demonstrated that FH can be caused by mutations in the LDLR gene. FH is an autosomal
dominant genetic disorder where there is a deficiency of LDLR activity. The absence of
functional LDLR in target organs especially in the liver results in the characteristic
clinical phenotype. Homozygotes have a qualitative loss of functional protein and are
severely affected and suffer from markedly elevated plasma levels of LDL-cholesterol,
the deposition of cholesterol in blood vessels, tendinous xanthomata and premature heart
attacks. Heterozygotes survive longer especially with treatment because they have
functional protein although at a reduced level.
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The frequency of heterozygous FH in Caucasian populations is reported to be 1/500 (0.2
percent) (Goldstein, Schrott et al. 1973). More than 800 LDLR variants have been
identified in FH subjects, and these genetic variants have been extensively reviewed
(Hobbs, Brown et al. 1992; Day, Haddad et al. 1997) and compiled online at two
websites: http://www.ucl.ac.uk/fh/ (Heath, Gahan et al. 2001) and
www.umd.necker.fr/LDLR/research.html (Villeger, Abifadel et al. 2002). Interestingly
not all of these variants are known to be functional.
Classification of functional LDLR mutations
There are five classes of functional LDLR mutations (Hobbs, Brown et al. 1992)
(Hobbs, Russell et al. 1990). Class 1 mutations result in no protein synthesis (null alleles)
due to disruptions of the promoter sequence, nonsense, frameshift, or splicing mutations.
Class 2 mutations disrupt transport of the LDL receptor from the endoplasmic reticulum
to the Golgi apparatus due to mutations in the ligand-binding and epidermal growth factor
precursor regions. Class 3 mutations are also primarily found in the ligand-binding and
epidermal growth factor precursor regions but interfere with cell surface binding of the
receptor to LDL. Class 4 mutations in the cytoplasmic and membrane-spanning domains
inhibit the clustering of LDL receptors on the cell surface, so that the bound LDL particle
is not internalized. Class 5 mutations in the epidermal growth factor precursor region
prevent the proper release of LDL particles in the endosome and, as a result, the LDL
receptor is not recycled to the cell surface.
The spectrum of hypercholesterolemia
Hypercholesterolemia refers to a blood cholesterol measurement >200 mg/dl. It is
estimated that more than 100 million Americans have total blood cholesterol above the
desirable levels (i.e. > 200 mg/dL). A cholesterol level of 200 to 239 mg/dl is considered
borderline high, and a level of ≥240 mg/dl is considered to be a high cholesterol
measurement (http://www.nhlbi.nih.gov/health/public/heart/chol/wyntk.htm).
Hypercholesterolemia (a.k.a. hypercholesteremia, hypercholesterinemia or type II
familial hyperlipoproteinemia) can be related to many factors, such as: a diet rich in
saturated fat, trans fatty acids (trans fats), and cholesterol; obesity; sedentary lifestyle;
increasing age; postmenopausal state; and, familial hyperlipidemias. The National
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Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) lays down
the following guidelines which consider the following values as desirable. Total
cholesterol level less than 200 mg/dL; LDL cholesterol < 100 mg/dL; HDL levels the
higher the better, 60 mg/dL or above is deemed to be protective (see website
http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.htm).
Clinical management
The clinical management of hypercholesterolemia is based on both cholesterol
measurements and the presence of cardiovascular risk factors. Nonpharmacologic
modalities are the first line of therapy. Options include low fat dietary modifications that
limit cholesterol (to less than 200 mg/day), and saturated fat (<7% of total calories). Life
style changes include regular aerobic exercise, cessation of smoking and counseling on
CAD risk factors. Chronic drug treatment is additionally employed in severe cases where
the goals are not reached by the above measures, or the values are considered high
relative to the existing CAD risk factors. For instance, patients with LDL >160 mg/dl;
LDL 130 to 159 mg/dl with two or more risk factors for CAD; LDL >100 mg/dl with
known disease such as CAD, vascular disease or diabetes mellitus are all candidates for
drug therapy. The physician can choose from cholesterol absorption inhibitors
(ezetimibe); Bile acid sequestrants; Niacin; HMG-CoA reductase inhibitors (Statins);
and, Fibric acids. The drugs can be tailored to suit the individual lipid profile, lifestyle so
as to decrease the side effects and maximize compliance.
LDLR variants could be aberrantly spliced
Mutations could alter splicing. This is to be expected when the base change
occurs in known splice site sequences. It is more difficult to appreciate the functional
consequences when the mutation affects cis-acting elements in the exons. The
polymorphisms could alter exon splicing by affecting either enhancers or silencers. In a
recent study of FH in Spain 39 novel mutations were identified, of which ~15% involved
splicing (Mozas, Castillo et al. 2004). Intronic mutations when present in regulatory
regions could result in splice variants and could lead to truncated proteins (Nissen,
Hansen et al. 1997).
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SR proteins are a part of the spliceosome
The splicing apparatus for GU-AG introns are made of small nuclear ribonucleic
acids (snRNAs) such as U1, U2, U4, U5 and U6. These are less than 200 nucleotides in
length and associate with proteins to become small nuclear ribonucleoproteins (snRNPs).
The snRNPs, together with other accessory proteins, bind to the transcript and ultimately
results in the spliceosome, the complex structure within which the actual splicing
reactions occur (Smith and Valcarcel 2000).
Splice-site selection is still a mystery, but it has become increasingly clear that a set of
splicing factors called SR proteins are important in this process of determining the correct
splice sites so that exons are not lost during splicing, and cryptic sites are ignored. The Cterminal domains of SR proteins contain an abundant number of serine (abbreviation S)
and arginine (R) amino acids. They are components of the spliceosome and are
implicated in the formation of a connection between bound U1-snRNP and bound U2AF
in the commitment complex (Valcarcel and Green 1996). This is believed to be important
for splice-site selection especially in conjunction with ESEs.
Exon Splicing Enhancer mutations can affect splicing and phenotype
Exon splicing enhancer (ESE) refers to purine-rich sequences located in exons
that can enhance splicing (Blencowe 2000). Inactivation of ESEs might be the underlying
cause of many human genetic diseases linked to mutations found in exons (Blencowe
2000). Nonsense, missense and silent mutations can inactivate genes by inducing
skipping of the mutant exons.
For instance, some cases of C5 deficiency in the immune system (Pfarr, Prawitt et al.
2005), spinal muscular atrophy, Becker muscular dystrophy, cystic fibrosis
transmembrane conductance regulator gene mutations (Aznarez, Chan et al. 2003), and
Tau exon 10 inclusion in frontotemporal dementia with Parkinsonism-chromosome 17
type (FTDP-17) could be due to disruption of functional ESEs (D'Souza and
Schellenberg 2000). Thus even innocuous looking coding-region SNPs that are predicted
to be translationally silent could turn out to be functionally malicious by virtue of
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affecting the splicing machinery. This could affect the phenotype by bringing about exon
skipping (Cartegni, Chew et al. 2002).
LDLR a good candidate for AD association study
The 18 exon, ~42,000 base pair LDLR gene is a strong candidate for AD
association studies for several reasons. First, the LDLR gene is located on chromosome
19p13.3, within a recently reported linkage peak in late onset, familial AD (Wijsman,
Daw et al. 2004). Second, LDLR is a receptor for apoE (Herz and Bock 2002); since
apoE variants are associated with AD, LDLR variants may also be associated with AD.
Third, LDLR is intimately linked with cholesterol homeostasis, which itself may emerge
as an AD modulator. The link between LDLR and cholesterol is supported by the facts
that LDLR mutations cause familial hypercholesterolemia (Pullinger, Kane et al. 2003)
while LDLR haplotypes appear associated with cholesterol levels and variance
(Knoblauch, Bauerfeind et al. 2002; Knoblauch, Bauerfeind et al. 2004). While high
cholesterol adversely affects both the cardiovascular system and the nervous system
(Marx 2001), recent observations have linked cholesterol and AD more specifically,
including that increased cholesterol alters APP processing to increase A levels in vitro
and possibly in vivo (reviewed in (Puglielli, Tanzi et al. 2003)), and that cholesterol
lowering drugs, statins, are associated with a lower AD prevalence in some observational
studies ((Jick, Zornberg et al. 2000; Wolozin, Kellman et al. 2000), reviewed in (Miller
and Chacko 2004)). In summary, since LDLR is a strong candidate gene for AD
association, the goal of this study was to evaluate LDLR SNPs and haplotypes for their
association with AD.
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Chapter Two: LDLr variants based on three single nucleotide polymorphisms

Rationale
The location of the LDLR gene, its function as an apoE receptor and in
cholesterol transport makes it a strong candidate gene for AD association studies as
explained in the introduction chapter. The goal of this study was to evaluate LDLR SNPs
and haplotypes for their association with AD.
Hypothesis
LDLR gene variants will associate with AD.
Specific Aims
In order to test the hypothesis we decided to answer the following specific questions.
Aim 1: To evaluate specific SNPs in the LDLR gene for association with AD in the UKY
Series.
Aim 2: To evaluate specific haplotypes constructed from the SNPs for association with
AD in the UKY Series.
Aim 3: To evaluate if any association that is found is reproducible in a second study
series (the ROS series).
Single Nucleotide Polymorphisms
Sequence variations within the genome are responsible for the phenotypic
differences observed between individuals that make them unique. Some of the very same
variations could also account for differential susceptibility to diseases. SNPs are one
particular type of variation, where there are single base nucleotide substitutions. This
could be a substitution involving potentially any of the four nucleotides A, T, G, or C but
usually only two alleles are present. It occurs as often as 1 kb in the genome making it the
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most abundant of genetic variations. They are about 1.4 million SNPs throughout the
genome with about 6% or a hundred thousand of them resulting in restriction fragment
length polymorphisms (RFLPs). Unlike RFLPs which could be laborious to analyze, all
SNPs are amenable to high throughput analysis using modern genotyping methodologies.
Genotyping methodology
Genomic DNA was extracted from peripheral blood leukocytes or autopsied brain
using routine methods. Samples were genotyped for apoE status by using a restriction
fragment length polymorphism approach (Hixson and Vernier 1990). Samples were
genotyped for LDLR SNPs by using unlabeled PCR primers and TaqMan MGB probes
(FAM and VIC dye labeled) obtained via the ‘Assays-by-Design’ service from Applied
Biosystems (Foster City, CA, USA).
For each individual SNP, the sequences of the forward primer, reverse primer, major
allele probe and minor allele probe are as follows: Exon10:
5'ACGGCGTCTCTTCCTATGACA3', 5'CAGCCAGCCCGTCGG3':
6FAMAGCAGGGACATCCMGBNFQ, VICAGCAGAGACATCCAGMGBNFQ; Exon
13: 5'AACTTGTTGGCTGAAAACCTACTGT3', 5'GCTGACCCACCCTTACCTCTT3':
VICTGTGGAAGAGAACCATMGBNFQ, 6FAMAAGAGGACCATATCCMGBNFQ;
Exon15: 5'TCCACAGCCGTAAGGACACA3', 5'CAGCCGGGAGGTGTCG3':
6FAMCACCCGGCCTGTTMGBNFQ, VICACCACCCGACCTGTMGBNFQ.
Statistical methodology
The Estimated Haplotype (EH) program was used to test for linkage
disequilibrium between alleles and between overall haplotypes and AD (Terwilliger J
1994); as reported elsewhere, the LDLR SNPs were in significant linkage disequilibrium
(Knoblauch, Bauerfeind et al. 2002). The indicated p values are nominal and are
considered significant if less than 0.05. Statistical Analysis System (SAS®) software
(SAS Institute, Inc., Cary, NC) was used for (i) chi-square (χ2) tests of allelic and
genotypic frequencies in persons with and without AD, (ii) determining odds ratios (OR),
95% confidence intervals (CI) and corresponding p values, and (iii) logistic regression to
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evaluate the influence of apoE4 (one degree of freedom (df)), gender, age (one df),
education (two df) and LDLR haplotype (two df).
Description and characterization of the study subjects from two distinct series:
A hypothesis-generating series was derived from a case-control study at the
University of Kentucky (UKY series) and a hypothesis-testing series was derived from a
cohort of the Religious Orders Study at the Rush University Medical Center (ROS
series).
UKY Series
In the UKY series, DNA for the non-demented, control individuals, i.e., non-AD
individuals, was obtained from the Biologically Resilient Adults in Neurological Studies
(BRAiNS) program (Schmitt, Wetherby et al. 2001). To be included within this study,
community volunteers were initially screened for alcohol or drug abuse, or psychiatric
illness, or dementia; they were then evaluated longitudinally through bi-annual physical
and neuropsychological dementia testing (Schmitt, Wetherby et al. 2001). AD individuals
within the UKY series were identified through the UKY Alzheimers Center Memory
Disorders Clinic; some of these individuals were initially within the BRAiNS program
and converted to a diagnosis of AD over time (see below). The UKY series included 133
non-ADs (51 males, average age at last visit 79.0 ± 7.0 years; 82 females, 78.4 ± 8.6
years), 97 persons with probable AD, and 21 with possible AD (32 males, average age at
diagnosis 73.5 ± 6.6 years; 86 females, 74.6 ± 8.4 years).
ROS Series
The ROS cohort was comprised of older Catholic nuns, priests, and brothers who
underwent annual neurological and cognitive performance testing as well as evaluation
by a physician with expertise in the evaluation of older persons for dementia. The
members of the ROS series included 69 non-AD individuals (36 males, average age 80.0
± 7.1 years; 33 females, 84.0 ± 5.4 years), 67 deceased persons with probable AD, and 19
with possible AD (37 males, average age at death 86.5 ± 6.6 years; 49 females, 88.8 ± 5.7
years).
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Thus within each series, the ages of AD and non-AD individuals were well matched. In
this study, the datasets presented were comprised entirely of Caucasians. For both series,
each subject was recruited following institutional review board-approved guidelines and
appropriate informed consent was obtained. In both the UKY and ROS series, control
individuals, i.e., non-AD individuals, were cognitively intact during the entire study
period. In both series, individuals diagnosed with AD represented a pool of persons with
a diagnosis of probable AD, i.e., met clinical criteria for AD without another condition
possibly contributing to dementia, and possible AD, i.e., met clinical criteria for AD and
had another condition, e.g., stroke, that was thought by the examining clinician to be
contributing to dementia. These clinical criteria and diagnoses were made following the
recommendations of the joint working group of the National Institute of Neurologic and
Communicative Disorders and Stroke and the Alzheimers Disease and Related Disorders
Association (NINCDS/ADRDA) (McKhann, Drachman et al. 1984).
ApoE association with AD serves as an internal positive control
To characterize the study subjects initially, we examined whether apoE4 was
associated with altered AD odds in the UKY and ROS series. Table 2-1 shows the
distribution of apoE4 according to disease status in each series. ApoE4 was significantly
associated with AD in both groups, confirming the reports of many others (reviewed in
(Rocchi, Pellegrini et al. 2003)) and suggesting that apoE should be evaluated as a
potential confounding factor. Thus after ascertaining that the study series are
representative we proceeded to test aim one.
Characterization of SNPs chosen for this study
Three SNPs in LDLR were chosen for this association study (see Table 2-2 and
Figure 2-1). They are all common SNPs i.e. > 0.10 in minor allele frequency. All the
three SNPs are in the coding region of the gene and are synonymous i.e. do not result in
any amino acid changes. They were chosen because they have been previously examined
and shown to be useful in constructing haplotypes (Knoblauch, Bauerfeind et al. 2002).
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Results from UKY Series - Hypothesis Formulation:
Single locus analysis for association with AD
In order to test specific aim 1 we evaluated three exonic SNPs from LDLR (Table
2-2) in our hypothesis generating sample, i.e., the UKY series. Table 2-3 shows
genotypic and allelic frequencies. After ascertaining that both the non-AD and AD series
were in Hardy-Weinberg equilibrium, we tested the null hypothesis that there is no
association between a SNP and AD, the alternate being that there is an association. None
of the SNPs associated significantly with AD (Table 2-3). The exon 13 SNP has been
evaluated previously with similar results (Lendon, Talbot et al. 1997). The LDLR SNPs
were also not significantly associated with AD after parsing for apoE4 status.
Multi locus or haplotypic analysis for association with AD
Since a haplotypic analysis can provide insights regarding additional SNPs that
have not been evaluated but are in linkage disequilibrium with the studied SNPs, we next
evaluated whether LDLR haplotypes were associated with AD. As part of testing specific
aim 2 unambiguous haplotypes could be assigned to 126 subjects who were either
homozygous for each the three polymorphisms or heterozygous at only one of the three
polymorphisms (Table 2-4). The resulting haplotypic frequencies were similar to those
published elsewhere (Knoblauch, Bauerfeind et al. 2002). Inspection of the results
suggested that the 211 haplotype was associated with AD, and, indeed, the 211 haplotype
was associated with a lower odds of AD (OR=0.48, CI=0.24-0.95, p= 0.03) (nominal p
value of 0.03, χ2 analysis of 211 against all other haplotypes). Hence, although
corrections for multiple testing would render this result non-significant, we interpret these
data as suggesting the hypothesis that the 211 LDLR haplotype is associated with lower
odds of AD.

Results from ROS Series - Hypothesis Testing:
Haplotypic analysis reveals association of 211 with AD
We then proceeded to evaluate this hypothesis per se in the ROS series, thus
addressing specific aim 3. The allele and genotype frequencies for the LDLR SNPs
(Table 2-5) were determined along with the resulting unambiguous 211 and non-211
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LDLR haplotypes (Table 2-6). Interestingly, although we were not formally testing
individual SNPs and odds of AD, we noted that the exon 10 SNP alone was associated
with odds of AD in this cohort. The 211 haplotype was significantly associated with
decreased odds of AD (OR=0.40, CI=0.19-0.84, p= 0.01). This association remained
significant when controlled for apoE status, age, gender and education by logistic
regression analyses (p=0.03).
Lastly, when we combined the ROS and UKY data sets, the significance of the
association between the 211 LDLR haplotype and the odds of AD increased, as expected
( OR=0.44, CI=0.26-0.73, p= 0.001, Table 2-7). We also analyzed the dose dependency
of the 211 LDLR haplotype and odds of AD (Table 2-8), which suggested that increasing
copy number was associated with a reduced odds of AD (OR = 0.46, CI= 0.26-0.84, p=
0.01). Hence, the 211 LDLR haplotype appears associated with lower odds of AD.
Discussion
The primary finding of this study was that the 211 LDLR haplotype associates
with a lower likelihood of AD in two different AD/non-AD series. These results are
significant for two primary reasons. First, an association between LDLR haplotypes and
AD suggests a new genetic link between AD, apoE, and cholesterol because the LDLR is
an apoE receptor and intimately involved in cholesterol homeostasis (reviewed in (Herz
and Bock 2002; Pullinger, Kane et al. 2003)). Second, these studies are generally
significant in that identifying genetic AD risk factors will aid in early diagnosis, and
facilitate drug discovery by identifying patients at high risk for AD prior to
symptomology. Moreover, these studies may lead to the discovery of novel molecular
mechanisms underlying AD, and thereby suggest new therapeutic approaches.
Within this study, we used the UKY subjects to generate a hypothesis that was then tested
in ROS. In doing so, we minimized concerns about multiple testing issues. However, we
noted additional findings that merit discussion. First, among the LDLR haplotypes
evaluated by Knoblauch et al., the 211 haplotype was associated with cholesterol values
near the mean (Knoblauch, Bauerfeind et al. 2002). Although the relationship between
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cholesterol in the periphery and CNS is unclear, this association may be consistent with
the possibility that “normal” cholesterol (reviewed in (Puglielli, Tanzi et al. 2003; Miller
and Chacko 2004)) and the 211 LDLR haplotype appear associated with reduced AD
odds.
The second finding that merits comment is that the UKY and ROS series differed in that
the exon 10 SNP was associated with AD in the ROS but not the UKY series (Table 2-3,
2-5). We have identified two possible explanations for this difference. First, we
recognized that the average age at diagnosis of the UKY series was some 14 years earlier
than the average age at death of the ROS AD subjects. Therefore, we parsed the UKY
series to generate a subset that matched the AD age in the ROS series, i.e., by using only
UKY AD individuals diagnosed at the age of 77 years or greater, or UKY non-AD
individuals last observed at the age of 77 years or greater, we generated post hoc a series
that contained 81 non-AD individuals (average age at last visit 83.9 ± 4.9 years), and 48
persons with AD (average age at diagnosis 81.2 ± 4.0 years); given that the average
duration from diagnosis to death is approximately 5-8 years, an average age of diagnosis
of 81 may be roughly comparable to an average age at death of 88 years. When the exon
10 SNP was analyzed within this subset, the exon 10 SNP frequency was 42% in the nonAD and 27% in the AD group, respectively (nominal p value 0.03), a result which mimics
that of the ROS series. Hence, one possible explanation for the UKY/ROS discrepancy
is that the AD ages of the two series are different. A second explanation for this
difference may be attributed to the case-control versus cohort nature of the two series.
The exon 10 SNP frequency in the AD individuals in the ROS and UKY series was
similar, i.e., 31.9% and 34.6%, respectively. Moreover, the non-AD exon 10 SNP
frequency in the ROS population, 44.9%, is similar to that reported for a European
population, 43.5% (Knoblauch, Bauerfeind et al. 2002). However, the exon 10 SNP
frequency in the UKY non-AD subjects was 37.2%. If the exon 10 SNP frequency in the
UKY AD subjects was compared with the European or ROS non-AD frequency, the
UKY AD series would approach significance. In summary, we are unclear as to why
these two series differ with respect to the exon 10 SNP association with AD but speculate
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that this association may be most discernible in individuals in their 8th decade, and/or in
prospective, cohort-based series.
The third issue that merits comment is that an EH analysis, which is based on predicted,
or ambiguous haplotypes did not reach significance in either the ROS or UKY series
(data not shown). In considering the interpretation of this analysis versus the
unambiguous haplotype analysis, we recognized that the primary difference was that the
unambiguous haplotype analysis did not include individuals that were heterozygous at
more than one position, e.g., 211/121 heterozygotes. Examination of the complete data
from UKY and ROS series (Table 2-9) suggests that the 211 haplotype has its most
robust effect when the second haplotype within the individual is 21X. Hence, we
speculate that the odds associated with the 211 LDLR haplotype are attenuated in the EH,
predicted haplotype analysis because this analysis includes individuals that are likely
211/12X heterozygotes, and the 12X haplotype carries a polymorphism that blunts the
effects of the 211 haplotype. This speculation requires experimental evaluation.
Since the LDLR SNPs did not alter the amino acid coding sequence, the mechanistic
underpinnings of this association study are unclear. However, the link between AD,
cholesterol and genetic variants is derived from multiple angles, including (i) the apoE4
polymorphism has been associated with increased cholesterol and increased AD risk
(reviewed in (Puglielli, Tanzi et al. 2003); (ii) SNPs in other members of the LDLR
family, including oxidized-LDLR and LDLR-related protein (LRP), as well as SNPs in
enzymes involved with cholesterol homeostasis, including cholesterol 24-hydroxylase
(CYP46) and acyl-coenzyme A, have been implicated in AD risk in at least some series
(Clatworthy, Gomez-Isla et al. 1997; Kang, Saitoh et al. 1997; Bertram, Blacker et al.
2000; Desai, DeKosky et al. 2002; Kolsch, Lutjohann et al. 2002; Lambert, LuedeckingZimmer et al. 2003; Papassotiropoulos, Streffer et al. 2003; Wollmer, Streffer et al.
2003). Although the LDLR-associated risk observed here is independent of apoE4 status,
we speculate that possible compensation among LDLR family members may confound
association studies evaluating individual family members; (iii) increased cholesterol is
associated with increased levels of Aß, a protein that appears critical to AD (reviewed in
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(Puglielli, Tanzi et al. 2003)); (iv) statin use lowers cholesterol levels and may decrease
AD risk (reviewed in (Miller and Chacko 2004)).
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Table 2-1: ApoE4 is associated with increased odds of AD in UKY and ROS
subjects
Series

AD

Non-AD

ApoE4 copy#

n (%)

n (%)

UKY

111 (100.0)

133 (100.0)

0

49 (44.1)

93 (69.9)

1

48 (43.2)

38 (28.6)

2

14 (12.6)

2 (1.5)

ROS

87 (100.0)

69 (100.0)

0

51 (58.6)

56 (81.2)

1

32 (36.8)

13 (18.8)

2

4 (4.6)

0 (0.0)

These data show the numbers and frequencies of individuals carrying 0, 1 (heterozygous),
or 2 (homozygous) copies of apoE4 in the AD and non-AD subjects. These odds ratios
(OR) were similar to those reported in other studies (Saunders, Strittmatter et al. 1993;
Roses 1994), e.g., the presence of apoE4 was significantly associated with AD in each
series (UKY: OR = 2.91, CI= 1.73-4.92, p= 0.00005, ROS: OR=2.97, CI=1.43-6.15,
p=0.003).
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Table 2-2: LDLR SNPs selected for association study
SNP
Position

NCBI
SNP

Synonym

Minor Allele
Frequency

Cluster ID

Nucleotide
exchange
1/2

Amino acid
exchange

Exon 10

rs5930

WIAF-10989

0.358

G/A

RR

Exon 13

rs5925

WIAF-10994

0.476

T/C

VV

Exon 15

rs5927

WIAF-10996

0.221

G/A

RR
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Table 2-3: LDLR Genotypic and Allelic Counts and Frequencies for the UKY series
SNPs

AD n (%)

Non-AD n (%)

χ2 (p value)

Genotype

114 (100.0)

133 (100.0)

0.40 (0.82)

1/1

47 (41.2)

51 (38.3)

1/2

55 (48.2)

65 (48.9)

2/2

12 (10.5)

17 (12.8)

Allele

228 (100.0)

266 (100.0)

1

149 (65.4)

167 (62.8)

2

79 (34.6)

99 (37.2)

Genotype

115 (100.0)

129 (100.0)

1/1

27 (23.5)

40 (31.0)

1/2

63 (54.8)

62 (48.1)

2/2

25 (21.7)

27 (20.9)

Allele

230 (100.0)

258 (100.0)

1

117 (50.9)

142 (55.0)

2

113 (49.1)

116 (45.0)

Genotype

115 (100.0)

131 (100.0)

1/1

74 (64.3)

75 (57.3)

1/2

34 (29.6)

50 (38.2)

2/2

7 (6.1)

6 (4.6)

Allele

230 (100.0)

262 (100.0)

1

182 (79.1)

200 (76.3)

2

48 (20.9)

62 (23.7)

Exon 10

0.35 (0.55)

Exon 13
1.81 (0.40)

0.85 (0.36)

Exon 15
2.10 (0.35)

0.55 (0.46)

This table refers to the SNPs in exon 10, 13 and 15 with 1 denoting the major allele and 2
the minor allele. The actual number and frequency (%) are displayed.
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Table 2-4: Unambiguous LDLR haplotypes in the UKY series
Haplotypes

AD n (%)

Non-AD n %)

Total n (%)

111

24 (20.0)

20 (15.2)

44 (17.5)

112

3 (2.5)

6 (4.5)

9 (3.6)

121

61 (50.8)

59 (44.7)

120 (47.6)

122

3 (2.5)

3 (2.3)

6 (2.4)

211

14 (11.7)

29 (22.0)

43 (17.1)

212

15 (12.5)

15 (11.4)

30 (11.9)

Total

120 (100.0)

132 (100.0)

252 (100.0)

chromosomes
The three positions in the haplotype refer to the SNPs in exons 10, 13 and 15,
respectively, with 1 denoting the major allele and 2 the minor allele. Unambiguous
haplotypes were discerned for 126 subjects, i.e., 50% of the total. Chromosomal number
and frequency (%) for AD and non-AD subjects are displayed. Although the 211
haplotype was not significantly associated with gender or apoeE4 status (p>0.05), the 211
haplotype was associated with a lower odds of AD (OR=0.48, CI=0.24-0.95, p= 0.03).
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Table 2-5: LDLR Genotypic and Allelic Counts and Frequencies for the ROS series.
SNPs

AD n (%)

Non-AD n (%)

χ2 (p value)

Genotype

83 (100.0)

68 (100.0)

9.07 (0.01)

1/1

34 (41.0)

21 (30.9)

1/2

45 (54.2)

33 (48.5)

2/2

4 (4.8)

14 (20.6)

Allele

166 (100.0)

136 (100.0)

1

113 (68.1)

75 (55.1)

2

53 (31.9)

61 (44.9)

Genotype

83 (100.0)

69 (100.0)

1/1

19 (22.9)

28 (40.6)

1/2

48 (57.8)

31 (44.9)

2/2

16 (19.3)

10 (14.5)

Allele

166 (100.0)

138 (100.0)

1

86 (51.8)

87 (63.0)

2

80 (48.2)

51 (37.0)

Genotype

81 (100.0)

67 (100.0)

1/1

50 (61.7)

38 (56.7)

1/2

29 (35.8)

24 (35.8)

2/2

2 (2.5)

5 (7.5)

Allele

162 (100.0)

134 (100.0)

1

129 (79.6)

100 (74.6)

2

33 (20.4)

34 (25.4)

Exon 10

5.31 (0.02)

Exon 13
5.52 (0.06)

3.88 (0.05)

Exon 15
2.09 (0.35)

1.05 (0.31)

This table refers to the SNPs in exon 10, 13 and 15 in the ROS series. The number of
individuals and frequencies (%) are displayed. Although we were not formally testing
the statistical significance of these results, we have included χ2 and p values for the sake
of completeness.
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Table 2-6: Unambiguous 211 and non-211 LDLR haplotypes in ROS series.
Haplotypes

AD

Non-ADs

Total

211

12 (14.6)

27 (30.7)

39 (22.9)

Non-211

70 (85.4)

61 (69.3)

131 (77.1)

Total

82 (100.0)

88 (100.0)

170 (100.0)

This table presents the unambiguous 211 and non-211 LDLR haplotypes for the AD and
non-AD individuals within the ROS series. The 211 haplotype was associated with a
lower odds of AD (OR=0.40, CI=0.19-0.84, p= 0.01).
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Table 2-7: Unambiguous LDLR haplotypes in the combined UKY and ROS series
Haplotypes

AD n (%)

Non-AD n (%)

Total n (%)

211

26 (12.9)

56 (25.5)

82 (19.4)

Non-211

176 (87.1)

164 (74.5)

340 (80.6)

Total

202 (100.0)

220 (100.0)

422 (100.0)

The 211 haplotype was associated with a lower odds of AD (OR=0.44, CI=0.26-0.73, p=
0.001).
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Table 2-8: 211 LDLR haplotype copy number in the combined UKY and ROS series
# 211 haplotype

AD n (%)

Non-AD n (%)

0

78 (77.2)

67 (60.9)

1

20 (19.8)

30 (27.3)

2

3 (3.0)

13 (11.8)

Total

101 (100.0)

110 (100.0)

These data show the frequencies of individuals carrying 0, 1 (heterozygous), or 2
(homozygous) copies of the 211 LDLR haplotype in the combined AD and non-AD
series. The presence of the 211 LDLR haplotype was significantly associated with AD
(OR = 0.46, CI= 0.26-0.84, p= 0.01).
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Table 2-9: Complete data from UKY and ROS series
Exon 10

Exon 13

Exon 15

rs5930

rs5925

rs5927

G(1)/A(2)

T(1)/C(2)

G(1)/A(2)

1/1

1/1

1/1

1/2

2/2

1/2

1/1

1/2

2/2

2/2

1/1

1/2

2/2

UKY
Haplotypes

ROS

AD

Non-AD

AD

Non-AD

n (%)

n (%)

n (%)

n (%)

111/111

1 (0.9)

3 (2.4)

2 (2.5)

0 (0.0)

1/2

111/112

1 (0.9)

0 (0.0)

0 (0.0)

0 (0.0)

2/2

112/112

0 (0.0)

1 (0.8)

0 (0.0)

0 (0.0)

1/1

111/121

16 (14.2)

8 (6.3)

11 (13.9)

9 (13.4)

1/2

Ambiguous

5 (4.4)

7 (5.5)

4 (5.1)

2 (3.0)

2/2

112/122

--

--

--

--

1/1

121/121

21 (18.6)

24 (18.9)

13 (16.5)

9 (13.4)

1/2

121/122

3 (2.7)

3 (2.4)

2 (2.5)

1 (1.5)

2/2

122/122

--

--

--

--

1/1

111/211

5 (4.4)

6 (4.7)

9 (11.4)

8 (11.9)

1/2

Ambiguous

6 (5.3)

8 (6.3)

4 (5.1)

1 (1.5)

2/2

112/212

2 (1.8)

4 (3.1)

0 (0.0)

5 (7.5)

1/1

Ambiguous

26 (23.0)

25 (19.7)

12 (15.2)

5 (7.5)

1/2

Ambiguous

16 (14.2)

20 (15.7)

17 (21.5)

14 (20.9)

2/2

Ambiguous

0 (0.0)

1 (0.8)

1 (1.3)

0 (0.0)

1/1

121/221

--

--

--

--

1/2

Ambiguous

--

--

--

--

2/2

122/222

--

--

--

--

1/1

211/211

3 (2.7)

6 (4.7)

0 (0.0)

7 (10.4)

1/2

211/212

3 (2.7)

11 (8.7)

2 (2.5)

5 (7.5)

2/2

212/212

5 (4.4)

0 (0.0)

1 (1.3)

0 (0.0)

1/1

211/221

--

--

1 (1.3)

0 (0.0)

1/2

Ambiguous

--

--

0 (0.0)

1 (1.5)

2/2

212/222

--

--

--

--

1/1

221/221

--

--

--

--

1/2

221/222

--

--

--

--

2/2

222/222

--

--

--

--

Total

113 (100.0)

127 (100.0)

79 (100.0)

67 (100.0)

These data reflect the overall results for this study and are included to facilitate eventual
meta-analyses.
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Figure 2-1: Schematic of the three SNPs along the LDLR pre mRNA
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11

12

13 14

15

The diagram is not drawn to scale with regard to the length of the introns or exons. It is
displayed so that the reader can appreciate the location of the three different SNPs.
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Chapter Three: The hunt for the functional SNP

Rationale
This chapter focuses on understanding the mechanism whereby a genetic variation
within the LDLR modulates LDLR function. The primary finding in our earlier study
was that the 211 LDLR haplotype associates with a lower likelihood of AD in two
different AD/non-AD series. Conversely the non 211 haplotypes are associated with
increased odds of AD. Since the LDLR SNPs did not alter the amino acid coding
sequence, the mechanistic underpinnings of this association study are unclear. Nearly
fifty percent of the unambiguous haplotypes are formed by 121. It is possible that the 121
haplotype carries a polymorphism that blunts the effects of the 211 haplotype. This
speculation requires experimental evaluation and that is exactly what we propose to do in
this study. This chapter seeks to address the question as to what is the mechanism
whereby a genetic variation within the LDLR genomic sequence modulates LDLR
function.
Hypothesis
The haplotypes harbour one or more functional SNP/SNPs
Global Specific Aim
To identify linked SNP(s) within the haplotypes with physiologic function
Specific Aim1: To identify additional SNP(s) within the predetermined
haplotypes by sequencing individuals displaying these haplotypes.
Specific Aim2: To perform theoretical evaluation of any identified SNP(s) for
potential functional capacity using predictive modeling tools and to choose promising
candidates
Specific Aim3: To test if any predicted effects actually occur in invitro/biologic
models- a qualitative study
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Specific Aim4: To test if the observed physiologic effect is associated with a
specific haplotype/SNP- a quantitative study
Sequencing DNA to indentify potentially functional SNP(s)
The goal of this study was to unearth other functional SNPs that may be driving
the LDLR haplotypic association with AD. We identified two individuals homozygous
for haplotypes 211 or 121 from our previous study and selected these individuals for
sequencing the exons and surrounding introns. We focused on the region between exon 9
and exon 14 using two complementary strategies. Our approach was to rapidly identify
variants in exon-intron boundaries.
Methods:
Genomic DNA of two haplotype 211 individuals and two haplotype 121
individuals was utilized in this study. Using standard molecular biology techniques
primer pairs were designed that would amplify specific exons along with ~100 bp of the
adjoining intron. Distinct bands were visualized by running on a polyacrylamide gel
electrophoresis (PAGE) apparatus and the individual bands sliced out of the gel and
purified using QIAEX II gel extraction kit (Qiagen) in isolation, taking care to avoid
contamination. About 100 ng of the purified pcr product was added to 3 uM of the
respective sense or antisense primer in separate reactions. The volumes were made up to
be 16 µl and sequenced at an off-site facility, Davis Sequencing (Davis, CA).
Results:
We chose to concentrate our work focusing on the region of exon 9 through 14
because the first two positions in our original haplotype appear to be the most robust and
are defined by the SNPs in exons 10 and 13 and we felt that this was the most logical
next step in our quest. In the course of sequencing the LDLR exons and adjoining introns
in genomic DNA from two individuals homozygous for having 211 and comparing them
with two individuals homozygous for 121 (the predominant non 211 haplotype), we
identified one additional SNP in an exon. This SNP was in exon 12 (rs688, T for C) and
the minor allele ‘T’ was found to label the 121 haplotype. There were several other SNPs
identified in introns. One in intron 9 and three in intron 11. The SNP position and minor
allele frequency for all of them are shown in Table 3-1. All of the SNPs have been
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previously identified and readily available at the NCBI website online. Intron 11 is 646
bp long and rs2738447 is the closest to exon 12 at 54 base pairs 5' to exon 12. These
SNPs appear to be differentiating the originally defined haplotypes. For instance the 211
haplotype is found to have 2---212---1 pattern in intron9--- intron11---exon12, which can
be better appreciated visually in Figure 3-1.
Theoretical evaluation of identified SNP(s) for potential functional capacity
Splicing of exon 12 is predicted to be affected by rs688
rs688 is a SNP located within exon 12, at a position 68 nucleotides from the 5’
end, at amino acid 591. This SNP has been previously identified and can be located
online at NCBI a publicly available database
(http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=688). This SNP has C as major allele
and T as minor allele and is fairly common with a minor allele frequency of about 0.33.
This abundant SNP has no prior clinical associations reported. The location of this SNP is
at codon position 3 and does not alter the amino acid (Asn) at number 591. As such, this
synonymous SNP is not predicted to effect the three dimensional structure of the protein
(Wang, Addess et al. 2007) or its interaction with its neighboring amino acid (Asn) in
position 570 in three dimensions
(http://www.ncbi.nlm.nih.gov/SNP/snp3D.cgi?rsnum=688). While searching for other
tools to evaluate this SNP, we came across ‘RESCUE-ESE Web Server’ an online tool
for identifying candidate ESEs in vertebrate exons (http://genes.mit.edu/burgelab/rescueese/). In brief ESEs are specific short oligo nucleotide sequences located in exons that
enhance pre-mRNA splicing. The authors of this tool were able to identify 238 hexamers
as candidate ESEs using a large database of human genes of known exon-intron structure
containing over 30,000 non-redundant exons (http://genes.mit.edu/burgelab/rescueese/ESE.txt). One of these hexamers is TCAACG. Interestingly, rs688 alters this
conserved DNA sequence termed an ESE element from the wild-type TCAACG to the
polymorphic TCAATG. This subtle shift from the wild-type sequence is predicted to
neutralize the ESE element such that the polymorphic sequence is not predicted to
enhance splicing as shown in Figure 3-2 ((Fairbrother, Yeh et al. 2002; Fairbrother,
Holste et al. 2004; Fairbrother, Yeo et al. 2004) on web at
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http://genes.mit.edu/burgelab/rescue-ese/). Similar results were found using ESEfinder
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home
(Cartegni, Wang et al. 2003; Smith, Zhang et al. 2006) as shown in Figure 3-3, 3-4). Thus
when the SNP is present, the predicted splicing enhancer function is neutralized. This
could result in an entire exon not being included in the transcript which has the potential
to dramatically influence the structure of the protein (Fairbrother, Holste et al. 2004).
Predicted effect of loss of exon 12
The amino acids in proteins are encoded by codons in the mRNA with a unit
length of three nucleotides. Exon 12 is 140 base pairs long which is not divisible by three,
the unit length of a codon, and its loss results not only in the loss of the amino acids
encoded by that exon but will also change the protein sequence encoded by the remaining
exons following it. The exclusion of this exon 12 is predicted to cause a frameshift in
exon 13, resulting in novel, carboxyl terminal sequences followed by a termination
codon; the resulting LDLR protein would retain the LDL-binding domain encoded by
exons 1-7 but lack the transmembrane domain encoded by exons 16-17 and hence in
theory will be a truncated, secreted form of LDLR that retains the ability to bind apoEcontaining lipoproteins. Similar secreted proteins are expected when the both exon 11
and 12 are spliced out. Both proteins will have identical sequence from the aminoterminus until the end of exon 10 but will have varying lengths of unique carboxyl
termini. Due to the aberrant splicing and the frame shift premature stop codons occur
well before the transmembrane domain encoding exons 16-17 and result in a truncated,
secreted form of LDLR.
A Qualitative study to examine alternative splicing of LDLR exon 12
The above mentioned effects are exciting. Do they actually happen in a
physiologically relevant model? Does this alternative splicing actually happen in the
brain? In order to address specific aim 3, we decided to set up the following experiment.
We selected human hippocampal brain samples that were generously provided by the
Sanders-Brown Alzheimers Disease Center Neuropathology Core. We used PCR to
amplify the LDLR region of exons 10 through 14 from pooled human hippocampal
cDNA samples, separated the DNA with polyacrylamide gel electrophoresis (PAGE),
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stained with SYBR Gold and visualize the DNA on a fluorescent imager. The identity of
the PCR products was determined by direct sequencing.
PCR amplification Strategy
Human hippocampal brain samples that were generously provided by the Sanders-Brown
Alzheimers Disease Center Neuropathology Core. The samples were from deceased
individuals and characterized previously. There were 25 samples in all and pooled human
hippocampal cDNA preparation was generated by taking 1 microliter of each sample and
mixing them together. The primer sequences are as follows, exon 10 sense 5’
CATCGTGGTGGATCCTGTTC 3’; exon 14 antisense 5’
GGTGGTCCTCTCACACCAGT 3’. PCR was performed on pooled human hippocampal
cDNA preparation PCR profiles consisted of pre-incubation at 94°C for 60 sec, followed
by 30 cycles of 94°C for 30s, 60°C for 45s, and 72°C for 90s (Perkin Elmer 9600). PCR
products were separated by polyacrylamide gel electrophoresis (PAGE) and visualized by
SYBR-gold fluorescence on a fluorescence imager (Fuji FLA-2000).
Sequencing Methodology
PCR product identities were determined by gel purification and direct sequencing (Davis
Sequencing). Distinct bands were visualized by running on a polyacrylamide gel
electrophoresis (PAGE) apparatus and the individual bands sliced out of the gel and
purified using QIAEX II gel extraction kit (Qiagen) in isolation, taking care to avoid
contamination. About 100 ng of the purified pcr product was added to 3 uM of the
respective sense or antisense primer in separate reactions. The volumes were made up to
be 16 µl and sequenced at an off-site facility, Davis Sequencing (Davis, CA).
Results
The PCR products upon separation by PAGE revealed multiple bands on analysis.
The above mentioned approach revealed a 451 bp pcr product that is the predominant
band comprising of exons 10 through 14 (which is the expected constitutive splicing
product which could lead to full length LDLR). Other PCR products that were detected
included a 311 bp band which could be due to a template lacking exon 12 and a 192 bp
band which could be due to a template lacking exons 11 and 12. Primers were designed
to anneal specifically to exon 10 and 14 of LDLR. This is ideal for studying the splicing

39

pattern of exon 12 and its neighbors because the bands will be well resolved and easily
distinguishable from one another if indeed there is alternative splicing.
The identity of each band was determined definitively by direct sequencing, and shown to
represent the alternative splicing patterns depicted in Figure 3-5. On close examination of
the results the predicted model is confirmed to be true. The sequencing yielded excellent
reads and were identical from either direction in the region of overlap. The exon
boundaries were not violated and the exons 11 and/or 12 were included or omitted in a
well defined manner.
Quantitative Splicing analyses: Compare splicing pattern of exon 12 in humans with
different genotypes for rs688
Having established that exon 12 can be alternatively spliced in the human brain
tissue from the hippocampus, I proceeded to address the question as to how much of this
alternative splicing occurs and if it associates with rs688. The goal was to identify
individuals homozygous for the rs688 alleles, generate human hippocampus cDNA
samples if needed and then analyze the splicing characteristics.
Methodology
The choice was made to work with select autopsy specimens generously provided
by the Sanders-Brown Alzheimers Disease Center Neuropathology Core. The cDNA or
genomic DNA from 25 individuals were genotyped for rs688, by using unlabeled PCR
primers and TaqMan MGB probes (FAM and VIC dye labeled) obtained via the ‘Assaysby-Design’ service from Applied Biosystems (Foster City, CA, USA) on an ABI-7000 or
ABI-7900 (Applied Biosystems).
cDNA preparation:
Total RNA was isolated from hippocampal autopsy samples from homozygous CC and
homozygous TT individuals. This RNA was then quantified by UV spectroscopy to
ascertain concentration and diluted to 1 ug per 5 ul to form a stock solution. It was then
converted to cDNA (SuperScript II, Invitrogen) by reverse transcription by standard
molecular techniques.
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PCR amplification and quantification:
The region from exon 10 to exon 14 was PCR-amplified (Platinum Taq, Invitrogen) by
using the primers specified earlier (refer section above), and the PCR products were
separated by PAGE and visualized by SYBR-gold staining on a fluorescent imager (Fuji
FLA-3000). To compare differences among RNA samples differential for the rs688 SNP,
PCR signal intensities were quantified with the fluorescent imager. In an effort to
improve the confidence in this assay background subtraction was performed within each
lane, and additional normalization was performed wherein the length of the various bands
were compared relative to the length of the full length exon 10-14 PCR product to obtain
accurate stoichiometry. The tissues were processed simultaneously and splicing
efficiency data obtained without regard to sex of the donor. For statistical analyses of
splicing efficiency, data from CC and TT homozygous individuals were separated and
analyzed by Students t test (StatSoft).
Results: rs688T is associated with decreased splicing efficiency in the brain
Out of the 25 samples we were able to identify 14 that were homozygous for rs688. To
investigate whether rs688 is associated with exon 12 splicing efficiency in the human
brain in vivo, we analyzed these 14 cDNA samples that were prepared from the human
hippocampus, a brain area that is affected in AD. Eight of these individuals were
homozygous for the major allele ‘C’ and six were homozygous for the minor allele ‘T’.
We focused on how much constitutive splicing occurs in the vicinity of exon 12 by using
appropriate PCR primers that anneal to exons 10 and 14. This approach revealed cDNA
corresponding to the expected full length LDLR, i.e., containing exons 10, 11, 12, 13, and
14 (due to constitutive splicing), as well as LDLR sequences that lacked exon 12, or 11
and 12 (due to alternative splicing). A representative image of these experiments is
shown in Figure 3-5. To compare the differences among RNA samples differential for the
rs688 SNP, PCR signal intensities were quantified with the fluorescent imager, and
normalized relative to the length of the full length exon 10-14 PCR product to obtain
accurate stoichiometry. The resulting percentages of full-length LDLR across exons 1014 as a function of rs688, the exon 12 SNP, are presented in Table 3-2.
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This assay revealed that rs688T associated with a significantly lower proportion of exon
12 containing full length LDLR mRNA in the brain (p<0.005, as shown in Table 3-2).
The apparent difference in splicing was about 13%. In summary, rs688 associates with
LDLR exon 12 splicing efficiency in the brain.
Compare the splicing pattern in human hippocampus vs cerebellum to check for
regional variability
The differences seen in the previous experiment could be attributed to either
phenotypic or genotypic differences. Phenotypic differences could be due to cell
population differences. AD for instance can damage the neurons in the hippocampus and
alter the ratio of neurons to astrocytes. Neurons are believed to express LDLR and hence
any decrease in the quantum of the receptor mRNA could be explained by presence of
fewer neurons that can synthesize LDLR. And if this is the case then if we compare
individuals with similar ratios of neuronal versus supporting cells in the hippocampus,
the full length mRNA levels will be the same. And by extension if we compare another
region of the brain that is relatively healthy the RNA levels will show no difference.
On the other hand it will be due to genotypic differences if we notice a persistence of the
difference in the splicing pattern when we analyze a different region of the brain that will
have a similar proportion of neurons versus supporting cells in all individuals. This could
be quickly checked by performing the same study using a different region of the brain
that is less vulnerable to the ravages of the neurodegenerative disorder. In this case I
chose to examine tissue from the cerebellum which is a region that is not affected in AD.
The exact methodology that was used to study the alternative splicing in the hippocampus
was now employed to analyze the cerebellum derived cDNA.
Results:
Twenty individual samples were located and cDNA from the cerebellum was analyzed
and compared to values obtained from the hippocampus. The results are provided in
Figure 3-6. The positive slope of the line and the fair degree of correlation between the
samples from the hippocampus and the cerebellum suggests that the differences are
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unlikely to be due to regional variability. Thus genotypic differences seem to be the
driving force for the splicing patterns observed.
Summary:
In this chapter we have discovered that the LDLR haplotypes of interest harbored
several additional SNPs. Out of these SNPs we narrowed our focus on rs688. We
identified that rs688 had the theoretical possibility for affecting splicing based on
prediction models. Then we showed that the splicing occurs in vivo, in human
hippocampus, and it varied based on the rs688 allele. The ESE prediction appears
accurate as analyzing LDLR splicing patterns in human hippocampal RNA shows that
individuals homozygous for rs688T have a significantly lower splicing efficiency.
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Table 3-1: LDLR SNPs identified by sequencing shown in context
NCBI SNP

Minor Allele

Nucleotide

Amino acid

Cluster ID

Frequency

exchange

exchange

Intron 9

rs1003723

0.40

T/C

----

Exon 10

rs5930

0.36

G/A

RR

Intron 11

rs2738445

0.43

T/C

----

Intron 11

rs2738446

0.29

C/G

----

Intron 11

rs2738447

0.28

C/A

----

Exon 12

Rs688

0.33

C/T

NN

Exon 13

rs5925

0.48

T/C

VV

Exon 15

rs5927

0.221

G/A

RR

SNP Position

The SNPs were identified by sequencing genomic DNA from two 211 homozygous
individuals and comparing them with two individuals homozygous for haplotype 121.
The identified SNPs are shown in the table along with the SNPs in exon 10, exon 13 and
exon 15 (highlighted in light grey) used to develop the original haplotypes.
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Table 3-2: rs688T is associated with decreased Full-Length LDLR mRNA
Rs688

FL LDLR from exon 10 –14
Mean±SE (n)

C/C

74.1 ± 4.3 (8)

T/T

61.0 ± 1.9 (6)

This table shows the association between the exon 12 SNP rs688 and the amount of full
length LDLR mRNA across exons 10-14. It shows the splicing efficiency in homozygous
C/C and T/T individuals along with the standard error and the actual number of samples.
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Figure 3-1: Schematic of various SNPs along the pre mRNA:

211
Ex10

11

12

13

14

15

Ex10

11

12

13

14

15

121

Legend
Minor
Major
Intron
Exon

The diagram is not drawn to scale with regard to the length of the introns or exons. It is
displayed so that the reader can appreciate the location of the different SNPs in table 3-1.
It shows that several additional SNPs appear to be different among the originally defined
haplotypes.
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Figure 3-2: Results from RescueESE program comparing influence of SNP rs688
SPECIES: human
sequence length 48 bp, fragment of LDLR exon 12, rs688 with C
total matches 4
unique matches 4

GAAGAC
TCAACG
GGAAGA
GGAGGA
CTCAAGCATCGATGTCAACGGGGGCAACCGGAAGACCATCTTGGAGGA
.........|.........|.........|.........|........
10
20
30
40

SPECIES: human LDLR
sequence length 48 bp, fragment of LDLR exon 12, rs688 with T
total matches 3
unique matches 3
GAAGAC
GGAAGA
GGAGGA
CTCAAGCATCGATGTCAATGGGGGCAACCGGAAGACCATCTTGGAGGA
.........|.........|.........|.........|........
10
20
30
40
The SNP rs688 is at position 19 (in bold face and underlined) and this figure shows that
when the sequence is analyzed with the RescueESE webtool as explained in the text, the
T allele can alter the ESE sequence and hence potentially affect splicing.
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Figure 3-3: Results from ESEfinder program comparing influence of SNP rs688
Seq

Motif

Position

Site

Score

rs688C SRp40

13

TGTCAAC 3.04512

rs688C SRp40

15

TCAACGG 3.01840

rs688T SRp40

15

TCAATGG 4.50965

The SNP rs688 is at position 19 and its effects are shown in tabular form. This shows that
the T allele can alter the ESE sequence resulting in lower threshold and loss of one of the
SRp40 binding motif and hence may affect splicing.
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Figure 3-4a: Graphical results for rs688C and SRp40 binding thresholds

Figure 3-4b: Graphical results for rs688T and SRp40 binding thresholds

The SNP rs688 is at position 19 and its effects are shown in graph form from ESEfinder.
The x axis represents the DNA sequences and the y axis represents the scores for the
SRp40 protein binding for rs688C (Figure 3-4a) and rs688T (Figure 3-4b). The threshold
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for binding is 2.67. Figure 3-4b predicts that the T allele can alter the binding sites for
this protein involved in splicing.
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Figure 3-5: An exon 12 SNP rs688 associates with alternative LDLR Splicing

rs 688
1Kb
Ladder T/T

C/C

Ex10

11

Ex10

11

Ex10

12

13

14

Exons 10-14
Full Length

13

14

Exon 12
Spliced

13

14

Exon 11 &
12 Spliced

Primers were designed to anneal specifically to exon 10 and 14 of LDLR. The PCR
products upon separation by PAGE revealed multiple bands on analysis. The above
mentioned approach revealed a 451 bp pcr product that is the predominant band
comprising of exons 10 through 14 (which is the expected constitutive splicing product
which could lead to full length LDLR). Other PCR products that were detected included
a 311 bp band which lacks exon 12 and a 192 bp band which lacks exons 11 and 12.
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Figure 3-6: RNA splicing and regional variability

Each data point indicates an individual. The x and y axis show the splicing efficiency of
full length 10-14mRNA in the Hippocampus and Cerebellum respectively.

Copyright © Rangaraj K. Gopalraj 2008
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Chapter Four: SNP rs688 and AD

Rationale
This chapter focuses on exploring the association of rs688 with AD. In the
previous chapter it was revealed that the LDLR haplotypes of interest harbored several
additional SNPs. Out of these SNPs I narrowed my focus on rs688. I identified that rs688
had the theoretical possibility for affecting splicing based on prediction models. Then it
was shown that the splicing occurs in vivo, in human hippocampus, and it varied based on
the rs688 allele. In additional experiments with other members in our lab we evaluated
the association of rs688 allele with exon 12 splicing efficiency in vivo further by
quantifying LDLR splicing in human anterior cingulate tissue obtained at autopsy and
found that the rs688T allele is associated with decreased LDLR exon 12 splicing
efficiency in aged males, but not females (Zou, Gopalraj et al. 2008). Thus rs688 can
modulate splicing in a sex dependant manner in the brain. This chapter will explore the
association of rs688 with AD. The body of work in this chapter will also seek to find out
if there is a sex dependant association in AD.
Hypothesis
The SNP rs688 will associate with AD in a gender specific reproducible manner.
Global Specific Aim
To test the SNP rs688 for association with AD and identify any gender specific
effects that could influence this interaction
Specific Aim1: To test the SNP rs688 for genetic association with AD in the ROS
series.
Specific Aim2: To test the effect of sex (male vs female) on this association in the
ROS series.
Specific Aim3: To test if the sex and disease specific associations are consistently
reflected in a larger population series
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In order to address the specific aims I began by genotyping and analyzing data
from the ROS series and then along with our collaborators study a large number of
individuals across three population series for genetic association of rs688 with AD. The
methodology for this chapter in its entirety is as described below.
Methodology for Genetic Studies
Study Population
Three different series (JS, RS-AUT, and ROS) were analyzed (as described in (Zou,
Gopalraj et al. 2008)). The JS series was collected through the Mayo Clinic Jacksonville
memory disorders clinic (Ertekin-Taner, Ronald et al. 2005). This study included 215 AD
men (mean age ± standard deviation: 79 ± 8) and 227 non-AD men (age: 78 ± 7) as well
as 362 women with AD (age: 78 ± 6) and 339 non-AD women (age: 78 ± 8). The RS
series was collected through the prospective, community-based Mayo Clinic AD registry,
as well as the Mayo Clinic Rochester memory disorders clinic (Ertekin-Taner, Ronald et
al. 2005). For this cohort, we obtained data for 188 men with AD (age at diagnosis: 81 ±
8, and 519 non-AD men (age: 78 ± 6), as well as 330 women with AD (age: 81 ± 8), and
607 non-AD women (age: 79 ± 6). The AD cases in the AUT series, which were
combined with the RS series, were obtained from brains with neuropathologically
confirmed AD that were collected at autopsy from Caucasians in Jacksonville, FL,
Rochester, MN and many additional sites, and included 235 men (age at death: 81 ± 6) as
well as 337 women (age: 85 ± 7). The ROS series represents the deceased members of
the larger, prospective, community-based ROS series and have been described elsewhere
(Gopalraj, Zhu et al. 2005). For this project, we used DNA from 37 men with AD (age:
86 ± 7), and 36 non-AD men (age: 80 ± 7), as well as 47 women with AD (age: 89 ± 6),
and 33 non-AD women (age: 83 ± 6). Clinical AD diagnoses on all series were made
with NINCDS-ADRDA criteria (McKhann, Drachman et al. 1984).
Genotyping Method
Genomic DNA was extracted from peripheral blood leukocytes or autopsied tissue by
using routine methods (Zou, Gopalraj et al. 2008). Samples were genotyped for rs688
and/or rs5925, a surrogate which is in near perfect linkage disequilibrium with rs688, by
using unlabeled PCR primers and TaqMan MGB probes (FAM and VIC dye labeled)
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obtained via the ‘Assays-by-Design’ service from Applied Biosystems (Foster City, CA,
USA) on an ABI-7000 or ABI-7900 (Applied Biosystems) (Zou, Gopalraj et al. 2008).
Statistical Analyses
The association of AD with rs688 was assessed by using logistic regression as adjusted
for series, age, sex and presence of apoE4 (Zou, Gopalraj et al. 2008). Models were fit
separately for males and females after strong evidence of an interaction of sex with the
effect of rs688 was found in a single model (Zou, Gopalraj et al. 2008). Tests of
interaction of rs688 by series, apoE4, and age were also conducted to evaluate whether
there was evidence of heterogeneity across series (Zou, Gopalraj et al. 2008). For apoE
and LDLR, the genotype frequencies in males and females from each series were
consistent with Hardy Weinberg equilibrium (Zou, Gopalraj et al. 2008).
Results
The data generated for all individuals across the three study series were analyzed
together as laid out in the methods section. But for the purposes of this chapter I will
initially present the findings from the ROS series in depth and then proceed to show the
cumulative findings of all three population series.
rs688T associates with AD in the ROS population
To test specific aim one the exon 12 SNP, rs688 was evaluated in the ROS series.
Table 4-1 depicts the genotypic and allelic counts and frequencies. I tested the null
hypothesis that there is no association between rs688 alleles and AD, the alternate being
that there is an association. The minor allele ‘T’ is more abundantly present in the AD vs
non-AD series, 48.2% vs 36.2% respectively. The SNP rs688 alleles associated
significantly with AD (p = 0.04 as shown in Table 4-1). This surprise finding though
unexpected is heartening, because based on the findings in our lab I know that sex can
influence the splicing efficiency in the brain. And so I was not expecting to find a robust
difference in a mixed population comprising both sexes.
rs688T associates with AD in males
The incidence and prevalence of AD varies by sex, with most studies drawing the
conclusion that females generally appear to be at higher risk than males (McDowell
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2001). Our lab has shown that rs688T allele is associated with decreased LDLR exon 12
splicing efficiency in human anterior cingulate tissue in aged males, but not females
(Zou, Gopalraj et al. 2008).
To address specific aim two the data from ROS series are presented in detail to
show rs688 and the genetic association with AD in men versus women. Table 4-2 depicts
the genotypic and allelic counts and frequencies for the males in the ROS series. It was
ascertained that both the non-AD and AD series were in Hardy-Weinberg equilibrium.
Then we tested the null hypothesis that there is no association between rs688 alleles and
AD, the alternate being that there is an association. The alleles for the SNP rs688
associated with AD significantly (p = 0.01 as shown in Table 4-2). The minor allele ‘T’ is
more abundantly present in the AD vs non-AD series, 54.1% vs 33.3% respectively.
Table 4-3 depicts the genotypic and allelic counts and frequencies for the females
in the ROS series. It was ascertained that both the non-AD and AD series were in HardyWeinberg equilibrium. Then I tested the null hypothesis that there is no association
between rs688 alleles and AD, the alternate being that there is an association. The alleles
for the SNP rs688 did not show any association with AD (p = 0.59 as shown in Table 43). The minor allele ‘T’ is still more abundantly present in the AD vs non-AD series,
48.2% vs 37.0% respectively.
rs688T associates with AD in males in three population series
I was able to work with our collaborators both here at the University of Kentucky
and outside and analyze whether rs688 associates with AD in a sex-dependent manner. In
all DNA was genotyped from 1,457 men and 2,055 women drawn from three case control
series. As described in the methods section these series were derived from clinically
diagnosed subjects at the Mayo Clinic Jacksonville, FL (JS) and the Religious Orders
Studies (ROS), as well as clinically diagnosed subjects at the Mayo Clinic Rochester,
MN, which were combined with a series of AD autopsies (RS-AUT) (Ertekin-Taner,
Ronald et al. 2005; Rogaeva, Meng et al. 2007; Zhu, Taylor et al. 2008). Analysis of the
association of AD with rs688 (recessive model) using logistic regression adjusted for
series, presence of apoE4, age and sex was performed (Zou, Gopalraj et al. 2008). The
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interaction terms for rs688 with series, and apoE4, was also considered and it was found
that there was strong evidence of an interaction of rs688 with sex (p=0.001), but no
evidence of heterogeneity in rs688 effects across series (p=0.46) or of interactions with
age (p=0.93) or the presence of apoE4 (p=0.45). Separate logistic regression models were
then used to analyze male and female data further (Zou, Gopalraj et al. 2008). Males with
genotype rs688T/T exhibited increased odds of AD (OR= 1.49, p=0.005, Figure 4-1)
(Zou, Gopalraj et al. 2008). However, in females, the estimated odds ratio was 0.79
(p=0.056), consistent with the sex-dependent splicing in the brain (Zou, Gopalraj et al.
2008). There was no significant difference in odds ratios among the three series for either
males or females, but the RS-AUT and ROS populations displayed a more robust
association in males than the JS series (Zou, Gopalraj et al. 2008). The statistical
significance of this finding in the male series overall was maintained even after
correction for multiple testing, for instance if the conservative Bonferroni correction is
utilized for testing allelic, recessive and dominant models it would adjust the overall pvalue to 0.015 (Zou, Gopalraj et al. 2008). Hence, the rs688T allele that is associated with
decreased splicing efficiency in tissue samples from males is also found to be associated
with increased odds of AD in males in the homozygous condition. In women the level of
significance was only marginal, especially after correcting for multiple testing. Therefore
I would cautiously interpret the results in women as suggestive evidence that rs688T may
be associated with reduced AD risk in women (Zou, Gopalraj et al. 2008). In summary,
rs688T/T is associated with increased odds of AD in males but not in females.
Discussion
The primary findings of this study is that rs688 is a functional SNP that associates
with LDLR exon 12 splicing efficiency in the human hippocampus and also associates
with significantly increased odds of AD in men. Hence, the overall significance of this
study is two-fold. First, these results specifically support the hypothesis that rs688 which
is a functional SNP in LDLR, a brain apoE receptor, is associated with AD in a sex
dependent manner. Second, the unusual sex-dependent association of rs688 with AD may
be relevant to other genetic variants or candidate genes in general (Zou, Gopalraj et al.
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2008). Other AD genetic studies may benefit by parsing the data based on sex and
analyzing men and women separately.
rs688 is a common SNP located within LDLR. By virtue of its location in an
excellent AD candidate gene, several prior studies have evaluated the association
between AD and rs688 or linked SNPs (Retz, Thome et al. 2001; Cheng, Huang et al.
2005; Gopalraj, Zhu et al. 2005; Bertram, Hsiao et al. 2007). When these studies were
undertaken, there was no awareness of any functional significance of rs688 or the
association with sex. Therefore the investigators did not parse their series by sex. For
instance even in this particular study if one were to analyze rs688 in males and females
combined together by logistic regression, after adjusting for series, presence of apoE4
and sex, one will find no association (Zou, Gopalraj et al. 2008). The overall OR for
rs688 in the recessive model was 1.04 (95% CI of 0.86-1.25, p=0.69). The lack of
association in women obscured the association resulting in an erroneous conclusion.
Hence, stratifying for sex makes a huge difference in detecting the association described
here. The use of a recessive model helped modestly in the detection of the association,
but was not critical. For instance even an allelic dosage model showed that while the odds
of AD for rs688C/T male individuals was equivalent to that of rs688C/C males
(OR=1.00, 95% CI of 0.78-1.27), rs688T/T males had an increased odds of AD (OR=
1.49, 95% of CI-1.09-2.04, p=0.013) (Zou, Gopalraj et al. 2008). In summary, I would
suggest that additional case control series must be analyzed to confirm this finding that
rs688T/T associates with increased odds of AD in male but not female subjects. I am
confident that further studies that are well designed and of sufficient size will confirm
these findings. And this expectation is also based on the demonstration of alteration in
biological function such as altered splicing efficiency.
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Table 4-1: LDLR rs688 Genotypic and Allelic Counts and Frequencies for the ROS
series.

SNPs

AD n (%)

Non-AD n (%)

χ2 (p value)

Genotype

84 (100.0)

69 (100.0)

5.14 (0.08)

1/1

21 (25.0)

29 (42.0)

1/2

45 (53.6)

30 (43.5)

2/2

18 (21.4)

10 (14.5)

Allele

168 (100.0)

138 (100.0)

1

87 (51.8)

88 (63.8)

2

81 (48.2)

50 (36.2)

rs688

4.44 (0.04)

This table refers to the distribution pattern of SNP rs688 in the ROS series in AD and
non-AD individuals. The number of individuals and frequencies (%) are displayed along
with the χ2 and p values.
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Table 4-2: LDLR rs688 Genotypic and Allelic Counts and Frequencies for the ROS
series - Males.

SNPs

AD n (%)

Non-AD n (%)

χ2 (p value)

Genotype

37 (100.0)

36 (100.0)

5.98 (0.05)

1/1

08 (21.6)

17 (47.2)

1/2

18 (48.6)

14 (38.9)

2/2

11 (29.7)

05 (13.9)

Allele

74 (100.0)

72 (100.0)

1

34 (45.9)

48 (66.7)

2

40 (54.1)

24 (33.3)

rs688

6.36 (0.01)

This table refers to the distribution pattern of SNP rs688 in the ROS series in AD and
non-AD males. The number of individuals and frequencies (%) are displayed along with
the χ2 and p values.
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Table 4-3: LDLR rs688 Genotypic and Allelic Counts and Frequencies for the ROS
series - Females.

SNPs

AD n (%)

Non-AD n (%)

χ2 (p value)

rs688
Genotype

47 (100.0)

33 (100.0)

1/1

13 (22.7)

12 (36.4)

1/2

27 (57.4)

16 (48.5)

2/2

07 (14.9)

05 (15.2)

Allele

166 (100.0)

138 (100.0)

1

86 (51.8)

87 (63.0)

2

80 (48.2)

51 (37.0)

0.76 (0.68)

0.28 (0.59)

This table refers to the distribution pattern of SNP rs688 in the ROS series in AD and
non-AD females. The number of individuals and frequencies (%) are displayed along
with the χ2 and p values.
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Figure 4-1: Rs688 is associated with AD in men. This Forest plot depicts the
OR and 95% CI for the association of rs688 with AD in each series, separately for men
and women. The bar width reflects the 95% CI while the symbol size reflects the relative
size of the series. The open diamonds represent the overall OR combining all three series
with the diamond width corresponding to 95% CI. The sample sizes for each genotype
for males were: rs688C/C (476), rs688C/T (704) and rs688T/T (277) while those for
females were rs688C/C (656), rs688C/T (1021) and rs688T/T (278).

Copyright © Rangaraj K. Gopalraj 2008
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Chapter Five: Conclusion and Future Directions
I am excited by the progression of our studies. I started with a promising
candidate gene, then identified an interesting haplotype, then I found a SNP that seemed
to label the haplotype, then I was able to predict the function by computational methods,
then confirmed the findings in several different models with help from members of the
Estus lab, and finally to associate the variant with disease. This final chapter will build on
these studies and explain our model in the context of other research in the field.
Primary findings
The primary findings of this study are four fold. First, the 211 LDLR haplotype
associates with a lower likelihood of AD in two different AD/ non-AD population series.
Second, the 211 haplotype does not contain the rs688T allele. Third, rs688T is associated
with reduced splicing efficiency of exon 12 in human hippocampus, an area of the brain
involved in AD. Fourth, this functional SNP rs688 associates with increased odds of AD
in men.
Overall significance
The overall significance of these studies are three-fold. First, these results
specifically support the hypothesis that a functional SNP in LDLR, a brain apoE receptor,
is associated with AD in a sex-dependent manner. Second, the unusual sex-dependent
association of rs688 with AD may be relevant to other genetic variants in general,
suggesting that AD genetic studies may benefit by analyzing men and women separately.
Third, these studies are generally significant in that identifying genetic AD risk factors
will aid in early diagnosis, and facilitate drug discovery by identifying patients at high
risk for AD prior to symptomology. Moreover, these studies may lead to the discovery of
novel molecular mechanisms underlying AD, and thereby suggest new therapeutic
approaches.
LDLR has many different roles, including cholesterol metabolism, apoE sequestration
and endocytosis. Other functions are emerging more slowly as more information becomes
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available, such as its ability to influence signaling through other family members and
competition for common ligands.
Although apoE and LDLR SNPs associate with both cholesterol and AD, we do not
interpret our results as supporting a positive correlation between peripheral cholesterol
and AD risk generally. ApoE4 and rs688T both associate with increased LDL-cholesterol
and increased AD risk but these associations have clear differences in their sex
dependence. The presence of an apoE4 allele in women is associated with a 5 mg/dl
increase in LDL-cholesterol (Schaefer, Lamon-Fava et al. 1994) and an increased AD
risk with an OR of 5.15 (95% CI of 4.23-6.27, data from this study). Males are similar in
that apoE4 is associated with a 3 mg/dl increase in LDL-cholesterol (Schaefer, LamonFava et al. 1994) and a 3.81 AD OR (95% CI 3.05-4.75). In contrast, rs688T is associated
with a 6 mg/dl increase in LDL cholesterol in women (Zhu, Tucker et al. 2007) but an
AD odds ratio of 0.79 (95% CI 0.62-1.01). Moreover, rs688T in men was associated with
an insignificant trend towards decreased cholesterol (Zhu, Tucker et al. 2007) but had an
odds ratio of 1.49 (95% CI 1.13-1.97) for AD risk. Thus the effects of apoE4 and rs688T
on peripheral cholesterol do not correlate with their effects on AD risk.
Model
For this reason, we interpret our data as suggesting that rs688 modulates LDLR
function with respect to cholesterol in the periphery and possibly with apoE metabolism
in the CNS. In the former, the relationship between LDLR and cholesterol has been wellsubstantiated; individuals with impaired LDLR function have less LDL-cholesterol
removed from the extracellular space, resulting in increased intracellular cholesterol
synthesis, further exacerbating plasma cholesterol levels (reviewed in (Hobbs, Brown et
al. 1992)). Hence, LDLR in the periphery is intimately linked with cholesterol
homeostasis per se. In contrast, LDLR deficiency in the brain does not alter brain
cholesterol, at least as modeled by the LDLR deficient murine brain (Fryer, Demattos et
al. 2005). Rather, LDLR deficiency increases murine brain apoE levels, as well as levels
of apoE3 and apoE4 in mice expressing these human alleles (Fryer, Demattos et al. 2005)
(Cao, Fukuchi et al. 2006). Since increased apoE expression associates with increased Aß
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pathology in the mouse (Holtzman, Fagan et al. 2000), the most parsimonious
interpretation of our data in men is a model wherein rs688T decreases exon 12 splicing
efficiency, leading to reduced functional LDLR and reduced apoE clearance, and thereby,
increased amyloid pathology and AD risk.
This model is supported by several additional lines of reasoning. First, the rs688T allele
increases the proportion of LDLR that lacks exon 12, which shifts the LDLR reading
frame, leading to a premature stop codon in exon 13 and a LDLR isoform lacking the
transmembrane domain encoded by exons 16-17; consistent with this possibility, a
similarly truncated LDLR produced by a nonsense mutation in exon 13 is retained within
the endoplasmic reticulum and causes familial hypercholesterolemia (Lehrman,
Schneider et al. 1987). Second, LDLR deficiency in murine models of amyloidogenesis
may exacerbate amyloid accumulation and memory deficits (Fryer, Demattos et al. 2005;
Cao, Fukuchi et al. 2006). Third, the association between rs688 and increased AD risk
was consistent with a recessive model; one can interpret this result as suggesting a
threshold effect, i.e., LDLR expression must be reduced below a critical threshold for AD
risk to be increased. Hence, while a partial reduction in LDLR due to a single rs688T
allele is insufficient to increase AD risk, a homozygous rs688T/T genotype is sufficient
to increase risk, consistent with the rs688T allele acting in a loss-of-function fashion. In
summary, the parsimonious interpretation of these results is a recessive model wherein
LDLR protein encoded by the exon 12-deficient LDLR isoform is not functional,
representing a loss of apoE receptor, reduced apoE clearance and increased risk for AD in
males (see model in Figure 5-1).
It is still unclear as to what are the underlying mechanism(s) restricting rs688 effects on
splicing to male brain tissue and female liver tissue (Zhu, Tucker et al. 2007). This
restriction may be more quantitative than qualitative as close inspection of the opposite
sex data, i.e., splicing efficiency in female brain tissue and male liver tissue, reveals
similar, albeit very modest trends. Further work in our lab has identified two related,
estrogen centric hypotheses that may account for these sex-dependent rs688 effects. First,
since (i) rs688T is predicted to neutralize an SRp40 binding site, (ii) SRp40 may be
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estrogen regulated (Tyson-Capper, Bailey et al. 2005), and (iii) estrogen levels in the
aged male are higher than those in the aged female due to aromatase acting upon
testosterone (Vermeulen, Kaufman et al. 2002), one can speculate that at least in the
brain, estrogen modulated SRp40 may account for rs688 sex-dependent actions. The
second model proposes that since estrogen acts upon the estrogen-response element in the
LDLR promoter to enhance LDLR expression (Li, Briggs et al. 2001), estrogen may also
modulate LDLR splicing by concurrent recruiting of splicing factors such as
CAPERalpha, as has been reported for estrogen actions on the transcription and splicing
of other genes (Auboeuf, Honig et al. 2002; Dowhan, Hong et al. 2005). In summary, one
can hypothesize that rs688 association with splicing in vivo in a sex-dependent fashion
reflects estrogen actions on SRp40 activity and /or splicing factor recruitment concurrent
with transcription.
Future Directions
These studies have advanced the understanding of the role of LDLR in AD. My
efforts have answered some questions, but while doing so it has raised more questions
that need to be answered. These additional studies can help elucidate the role of rs688 in
specific and LDLR in general in AD. The following are all valid questions to study and
answers are needed. Whether SRp40 plays a role in regulating the splicing efficiency of
LDLR? If so how? Does it recruit other cellular machinery directly by attracting them, or
indirectly by negating the suppressive influences of other regulatory elements in the
vicinity? Which splicing factors are involved in exon 12 alternative splicing? How
important is the promoter region in LDLR and is it differential with rs688T bearing
haplotypes?
One can design experiments to show that SRp40 is critical for alternative splicing of exon
12. SRp40 is supposed to bind in the region around rs688 as explained earlier in chapter
three. One can use site directed mutagenesis to change the nucleotides around rs688 to
show that when the footprint of the SR protein binding site is affected even the rs688C
allele results in decreased splicing efficiency. With better prediction models becoming
available with time one could also analyze the surrounding sequence for any silencer
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elements that could negatively affect constitutive splicing. This will be interest because it
will lend itself to further delineating the mechanism for SRp40s action in this instance, as
to whether it directly recruits other helpful splicing machinery to the site or releases the
repressive effects of a neighboring protein bound to a silencer element (exon splicing
silencers) in the gene. And one can employ the same technique of site directed
mutagenesis to change the nucleotides of the silencer element and study the effects on
splicing efficiency. If there are no predicted elements one may even identify new
regulatory elements if any over short stretches of DNA such as exon 12 by this approach.
One could also test if these effects are dependent on the RS domain which is a very
important part of the SR proteins by using truncated proteins that lack this domain. One
could study the effects of overexpressing or adding exogenous SRp40 or dominant
negative proteins on splicing efficiency in these models. SRp40 and its interactions
specifically with splicing factor U2AF35 and/or the snRNP protein U1-70K and splicing
co-activator Srm160 can also be studied. I believe this targeted approach can be very
fruitful in identifying the relevant players in this phenomenon. This could also help
delineate whether these effects are RS domain dependent or independent (Cartegni, Chew
et al. 2002).
It is known that there is a sterol-responsive element in the LDLR promoter that when
activated will result in activating the SCAP/SREBP pathway (Duriez 2003; Dou, Fan et
al. 2008; Morin, Nichols et al. 2008). One could sequence the promoter region from
individuals with high vs low splicing efficiency and try to identify any linked SNPs and
in functional assays one could investigate the effects of exogenous estrogen other steroids
and drugs on the promoter activity and splicing efficiency.
So far I have been talking about events that happen upstream that can influence the levels
of mRNA expression. But if the absolute amount of functional LDLR protein is a
determinant in AD one also would need to be concerned about downstream events. We
will need to look at the actual expression levels of LDLR protein. Some mechanisms that
can alter gene expression levels can have no apparent change in protein levels, but this
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again can be due to increased mRNA degradation or upregulation of other pathways that
can downregulate the cell surface protein levels, such as the serine protease proprotein
convertase subtilisin/kexin 9 (PCSK9). This will be instrumental in understanding the
specific effects of rs688 alleles and will also open the door to the study of other genes
and pathways that can influence the LDLR levels in general in association with AD. For
instance PCSK9 has been shown to have a role in regulating LDLR protein levels in rat
livers and this effect could be modulated by hormonal and dietary modalities (Persson,
Galman et al. 2008). Lipid lowering medications could also affect the PCSK9 effects on
LDLR (Gouni-Berthold, Berthold et al. 2008). It would be fascinating to study these
effects in brain tissue and the interplay of rs688 and other LDLR SNPs. This line of
investigation would advance the hypothesis that the amount of functional surface LDLR
plays a pivotal role in AD by possibly altering the apoE and amyloid beta clearance and
degradation, consistent with a recessive model for the biologic effects of rs688T
influenced truncated soluble LDLR in the brain.
Once the accuracy of this model is established, it will pave the way to investigate drugs
that increase LDLR and might be beneficial in AD. For instance statins can upregulate
the expression of the LDLR. The findings from these additional experiments might also
be applicable in lipid metabolism and cardiovascular disease. Also it will be interesting to
look at new emerging research and how that may affect the model that has been
developed from this study. For instance some studies suggest that gonadotrophins may be
important in the brain signaling. So much so in some instances it is not just the absence of
estrogens but the presence of gonadotrophins that can orchestrate multiple effects
(Webber, Casadesus et al. 2005). Also it is tempting to speculate that the soluble LDLR
can escape the ravages of PCSK9 and this might be deleterious especially in the
periphery where soluble LDLR could act in a dominant fashion.
Conclusion
In conclusion, rs688 is a common and functional LDLR SNP that modulates LDLR exon
splicing efficiency in vitro in neural cells and in vivo in the brain. Moreover, rs688
associates significantly with increased AD risk in men. Since LDLR expression in the
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CNS could be manipulated, e.g., by statins that penetrate the blood-brain barrier, these
results suggest that LDLR modulation may represent a therapeutic target in at-risk
populations. Overall, I anticipate these studies may prove useful for understanding the
role of sex and apoE receptors in AD. Moreover, these studies provide a model for
identifying AD susceptibility alleles by focusing on well-characterized functional SNPs
in genes likely to influence risk for AD.
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Figure 5-1: Model of rs688 effect on AD

This figure depicts the working model as to how rs688T could increase the odds of AD in
men. rs688T decreases exon 12 splicing efficiency, leading to reduced functional LDLR
and reduced apoE clearance, and thereby, increased amyloid pathology and AD risk.
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